[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 306
1. Bansal A, Zakhour HD: Benign mesothelioma of the appendix: an incidental finding in a case of sigmoid diverticular disease. J Clin Pathol; 2006 Jan;59(1):108-10
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mesothelioma of the appendix: an incidental finding in a case of sigmoid diverticular disease.
  • Benign multicystic mesothelioma is a well recognised but rare entity.
  • The aim of this report is to describe a case of a small mesothelial proliferation of the peritoneum.
  • An operation was performed for symptomatic sigmoid diverticular disease.
  • Microscopy revealed a benign mesothelioma.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Diverticulum / complications. Mesothelioma / diagnosis. Sigmoid Diseases / complications

  • Genetic Alliance. consumer health - Diverticular Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2002 Jul-Aug;54(4):569-72 [12239771.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):844-54 [3789251.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):375-8 [2181883.001]
  • [Cites] J Korean Med Sci. 1989 Jun;4(2):111-5 [2597362.001]
  • [Cites] G Ital Oncol. 1989 Jan-Mar;9(1):39-42 [2707838.001]
  • (PMID = 16394291.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860251
  •  go-up   go-down


2. Mourali M, Kedous Z, El Fekih C, Ben Haj Hassine A, Ayadi A, Zineb NB: [Unexpected diagnosis of a cystic pelvic mass: benign mesothelioma of the uterus: case report]. Tunis Med; 2010 Aug;88(8):605-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unexpected diagnosis of a cystic pelvic mass: benign mesothelioma of the uterus: case report].
  • [Transliterated title] Diagnostic Inattendu devant une masse kystique pelvienne : mésotheliome bénin de l’utérus. A propos d’un cas.
  • BACKGROUND: Benign mesothelioma is a rare tumour mostly found in the genital tract.
  • Histologic exam and immnunochemistry concluded to a benign cystic mesothelioma.
  • CONCLUSION: The benign mesothelioma of the uterus is usually discovered in histology, differential diagnosis for solid forms can be made with leiomyoma or adenomyoma, whereas the cystic forms can be discussed essentially with the ovarian cysts.
  • The presence of mesothelial immunophenotype in immunochemistry improves diagnosis.
  • [MeSH-major] Mesothelioma, Cystic. Uterine Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711970.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


3. Arsene D, Georgescu A, Dănăilă L, Ardeleanu C: Giant intracranial endolymphatic sac tumor (ELST). Case presentation and histogenetic considerations. Rom J Morphol Embryol; 2008;49(1):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant intracranial endolymphatic sac tumor (ELST). Case presentation and histogenetic considerations.
  • We present a giant tumor of the skull base compressing the brain in a 40-years-old man.
  • The tumor was policystic at imaging.
  • Its histopathology, immunohistochemical profile and long evolution suggest an endolymphatic sac tumor (ELST), a rare case of neoplasia.
  • This could be from either the organ of Corti or some local cells that generate a resemblance with a systemic tumor, the so-called benign mesothelioma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Humans. Male. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273509.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Chu PW, Liu JY, Peng YJ, Yu MH: Solitary fibrous tumor of the uterus. Taiwan J Obstet Gynecol; 2006 Dec;45(4):350-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the uterus.
  • OBJECTIVE: A solitary fibrous tumor is an uncommon soft-tissue tumor and rarely occurs in the uterus.
  • The results of frozen section showed benign mesothelioma-like tumor.
  • Unexpectedly, further histopathologic results of the lesion revealed a solitary fibrous tumor, an outcome that was subsequently confirmed by means of CD34 immunohistochemical stain.
  • CONCLUSION: The behavior of solitary fibrous tumors arising from the uterus is difficult to evaluate; therefore, complete surgical excision featuring clear margins and comprehensive follow-up is recommended.
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175498.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Uzüm N, Ozçay N, Ataoğlu O: Benign multicystic peritoneal mesothelioma. Turk J Gastroenterol; 2009 Jun;20(2):138-41
Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma.
  • Benign multicystic peritoneal mesothelioma is a rare tumor that occurs mainly in women in their reproductive age.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530048.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


6. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol; 2009 Dec;4(12):1480-4
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
  • In this pilot study, we investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) for differentiating asbestos-related benign pleural disease from malignant mesothelioma.
  • MATERIALS AND METHODS: The study population comprised 31 consecutive patients (17 malignant mesotheliomas, nine benign asbestos pleurisies, and five diffuse pleural fibrosis) with a mean age of 61 years between January 2006 and December 2008.
  • ROCs analyses for standardized uptake value (SUV) adjusted to body weight were calculated between benign and malignant pleural diseases.
  • RESULTS: 18F-FDG PET/CT imaging correctly detected the presence of malignancies in 15 of 17 patients with malignant mesothelioma for sensitivity, specificity, and overall accuracy of 88.2%, 92.9%, and 90.3%, respectively.
  • 18F-FDG PET/CT imaging correctly identified 13 of 14 cases of benign pleural disease.
  • The mean SUV values were 6.5 +/- 3.4 for malignant mesothelioma cases and 0.8 +/- 0.6 for benign pleural diseases (p < 0.001).
  • When we compared the two groups of pleural disease, a cut-off value of 2.2 for SUV gave the best accuracy with 94.1%, 100%, 100%, and 93.3% for sensitivity, specificity, positive predictive value, and negative predictive value, respectively.
  • CONCLUSION: Preliminary results of this trial provide evidence that 18F-FDG PET/CT imaging is a highly accurate and reliable noninvasive test to decide for further investigation of differentiating malignant mesothelioma from benign pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Fluorodeoxyglucose F18. Mesothelioma / radionuclide imaging. Pleural Diseases / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875971.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 1332-21-4 / Asbestos
  •  go-up   go-down


7. Asghar S, Qureshi N, Awan A: Benign mesothelioma of peritoneum presenting as a pelvic mass. J Coll Physicians Surg Pak; 2008 Nov;18(11):723-5
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mesothelioma of peritoneum presenting as a pelvic mass.
  • A large solitary multiloculated pelvic cyst in a 40-year-old woman with chronic pelvic pain was diagnosed to be a Multicystic Benign Mesothelioma (MBM) of peritoneum at laparotomy.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Ovarian Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis. Pelvic Pain / diagnosis. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983801.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


8. van Bijsterveldt C, Willemsen W, Bulten J: Peritoneal benign mesothelioma during and after two pregnancies. Eur J Obstet Gynecol Reprod Biol; 2006 Aug;127(2):265-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal benign mesothelioma during and after two pregnancies.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Pseudomyxoma Peritonei / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527388.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Ireland
  •  go-up   go-down


9. Addis B, Roche H: Problems in mesothelioma diagnosis. Histopathology; 2009 Jan;54(1):55-68
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Problems in mesothelioma diagnosis.
  • Many centres are now seeing increasing numbers of patients with malignant mesothelioma.
  • This presents pathologists involved in making the diagnosis with a number of problems, which can be divided into those encountered in making the distinction between mesothelioma and benign changes and those experienced in separating mesotheliomas from other types of epithelial and connective tissue tumours.
  • Immunohistochemistry plays a major role in helping to make the diagnosis, but it should be interpreted with due regard to the clinical setting and radiological features, and with a knowledge of the wide morphological variations seen in mesothelioma.
  • It includes a discussion of some of the less common variants of mesothelioma and other pleural-based tumours that enter into the differential diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054156.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 101
  •  go-up   go-down


10. Boldú J, Eguía VM: [Benign pleural diseases induced by asbestos]. An Sist Sanit Navar; 2005;28 Suppl 1:21-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign pleural diseases induced by asbestos].
  • Together with the prolonged latency existing between exposure and the disease, this means that for many years we will continue to see pleural clinical manifestations from past exposure, in spite of the increasingly limited use of asbestos in recent decades.
  • This exposure can show itself in different manifestations, both malign, such as mesothelioma, and benign, principally benign pleural effusion, pleural plaques, diffuse pleural fibrosis and massive atelectasis.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915168.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


11. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A: 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int; 2010 May;60(5):395-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
  • Homozygous deletion of 9p21, the locus harboring the p16 gene, has been reported as one of the most common genetic alterations in malignant mesotheliomas (MMs).
  • Previous studies showed that this alteration might be useful for differentiating benign from malignant mesothelial tumors in cytology and surgical specimens.
  • The purpose of this study is to evaluate the diagnostic utility of 9p21 homozygous deletion assessed by FISH in mesothelial neoplasm and hyperplasia of Japanese patients using paraffin-embedded tissue.
  • In contrast, no cases of adenomatoid tumor, benign mesothelial multicystic tumor, reactive mesothelial hyperplasia or pleuritis showed 9p21 deletion (P < 0.005).
  • 9p21 homozygous deletion correlated well with p16 protein expression in the tumor cells.
  • Our study suggests that 9p21 homozygous deletion assessed by FISH on paraffin-embedded tissue may be very useful for differentiating MM from reactive mesothelial proliferation.
  • [MeSH-major] Chromosomes, Human, Pair 9. Genes, p16. Heart Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Epithelium / pathology. Female. Gene Deletion. Gene Dosage. Humans. Pericardium / metabolism. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518890.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


12. Wheatley-Price P, Yang B, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho B, De Perrot M, Liu G: Mesothelin as a marker of response in malignant pleural mesothelioma. J Clin Oncol; 2009 May 20;27(15_suppl):7581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin as a marker of response in malignant pleural mesothelioma.
  • : 7581 Background: Malignant pleural mesothelioma (MPM) is a rare malignancy related to asbestos exposure.
  • Radiological assessment of disease status and treatment response using RECIST criteria is often difficult, therefore blood markers of disease burden may be useful adjunctively.
  • Soluble mesothelin related peptide (sMRP) can distinguish between MPM and benign pleural disease.
  • We performed an exploratory analysis to determine whether sMRP correlates with MPM disease course.
  • Changes in sMRP levels were compared with corresponding radiological tests, scored as progression, stable or disease shrinkage.
  • At study entry 34/37 (92%) patients with measurable disease had elevated sMRP (>9ng/ml, range 14-60).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963378.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Szöllósi A, Ferenc C, Pintér T, Erényi A, Nagy A: [Benign cystic mesothelioma, a rare tumor of the peritoneum]. Magy Seb; 2005 Feb;58(1):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign cystic mesothelioma, a rare tumor of the peritoneum].
  • [Transliterated title] Benignus cisztikus mesothelioma, a peritoneum ritka daganata.
  • We report the case of a 28-year-old woman, who presented with acute abdominal and pelvic pain, the appearance of appendicitis.
  • Final histology revealed benign cystic mesothelioma, which is a rare lesion of the peritoneum, occurring mainly in women in reproductive age.
  • The etiology of cystic mesothelioma is still unclear.
  • [MeSH-major] Mesothelioma, Cystic. Peritoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018599.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


14. Scherpereel A, Lee YC: Biomarkers for mesothelioma. Curr Opin Pulm Med; 2007 Jul;13(4):339-443
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Mesothelioma is an incurable cancer and its global incidence continues to increase.
  • There has been strong interest in the search for a biomarker that would be of value for the diagnosis, prognosis and disease monitoring of mesothelioma.
  • RECENT FINDINGS: To date, global gene profiling studies have failed to find a molecule that reliably captures all subtypes of mesothelioma, and differentiates it from benign pathologies and metastatic carcinomas.
  • False negatives are common with sarcomatoid mesothelioma.
  • SMRP levels may reflect tumor load and disease progression.
  • The role of SMRP in predicting mesothelioma development in subjects exposed to asbestos has raised interest.
  • Osteopontin lacks specificity as a diagnostic marker for mesothelioma but may have value in disease monitoring.
  • SUMMARY: The proposed markers have insufficient accuracy to replace cytohistology as the gold standard for diagnosis for mesothelioma.
  • Elevated SMRP levels raise suspicion of mesothelioma although negative values do not exclude disease.
  • Its role in disease monitoring in patients and in predicting disease development in at-risk individuals warrant further study.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / metabolism. Pleural Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534183.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


15. Stroescu C, Negulescu R, Herlea V, David L, Ivanov B, Nitipir C, Popescu I: [Recurrent benign cystic peritoneal mesothelioma]. Chirurgia (Bucur); 2008 Nov-Dec;103(6):715-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent benign cystic peritoneal mesothelioma].
  • [Transliterated title] Mezoteliom multichistic peritoneal recidivat.
  • The benign cystic peritoneal mesothelioma (BCPM) is a rare neoplasm affecting mainly females at reproductive age.
  • The clinical manifestations are insidious, uncharacteristic; the benign cystic peritoneal mesothelioma is often discovered during a surgical procedure addressing another condition.
  • There are no long term studies dictating a single therapeutic attitude but a high risk of local recurrences and the possibility of transformation into malignant mesothelioma have lead to the current tendency towards an aggressive treatment of the tumor.
  • We present the case of a recurrent benign cystic peritoneal mesothelioma in a 40 years old female patient, emphasizing the therapeutic approach and the role of radical surgery in the treatment of BPCM.
  • [MeSH-major] Mesothelioma, Cystic / surgery. Neoplasm Recurrence, Local / surgery. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274921.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


16. Vacharadze K, Burkadze G, Turashvili G, Kiria N: Argyrophilic nucleolar organizer regions in benign and malignant mesothelial lesions. Georgian Med News; 2005 Nov;(128):91-3
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Argyrophilic nucleolar organizer regions in benign and malignant mesothelial lesions.
  • The aim our study was to assess the usefulness of AgNOR stain in distinguishing between benign and malignant mesothelial lesions.
  • The patients were divided into three groups: group I -- reactive mesothelium (71 cases), group II -- hyperplastic mesothelium (66 cases), group III -- epithelial type mesothelioma (52 cases).
  • Our results show that AgNOR staining is useful to differentiate epithelial type mesothelioma and benign mesothelial lesions such as reactive and hyperplastic mesothelium.
  • AgNOR is highly sensitive, specific and cost-effective technology which can be used as an ancillary diagnostic approach for distinguishing between reactive and/or hyperplastic changes of mesothelium as well as in differential diagnosis of epithelial type mesothelioma.
  • [MeSH-major] Antigens, Nuclear / metabolism. Lung Diseases / metabolism. Lung Diseases / pathology. Neoplasms, Mesothelial / metabolism. Neoplasms, Mesothelial / pathology. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369075.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


17. Rappa F, Ternullo MP: [Adenomatoid tumor]. Pathologica; 2006 Apr;98(2):164-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor].
  • [Transliterated title] Tumore adenomatoide.
  • Adenomatoid tumour is a neoplastic process of discussed origin, but the immunohistochemical phenotype leads a mesothelial derivation.
  • In the present report we described a case of Adenomatoid tumour of the uterus body in a 46 years old patient.
  • [MeSH-major] Adenomatoid Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Calbindin 2. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Keratins / analysis. Leiomyoma / diagnosis. Middle Aged. Neoplasm Proteins / analysis. S100 Calcium Binding Protein G / analysis. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929792.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Calbindin 2; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


18. Søreide JA, Søreide K, Körner H, Søiland H, Greve OJ, Gudlaugsson E: Benign peritoneal cystic mesothelioma. World J Surg; 2006 Apr;30(4):560-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign peritoneal cystic mesothelioma.
  • BACKGROUND: Benign peritoneal cystic mesothelioma (BPCM) is a rare tumor of unknown origin, most frequently encountered in women of reproductive age.
  • Nevertheless, recurrent disease is not uncommon.
  • The natural history of this rare disease is less than well clarified.
  • [MeSH-major] Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Peritoneum / diagnostic imaging. Peritoneum / pathology. Peritoneum / surgery. Reoperation. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1165-7 [7541936.001]
  • [Cites] South Med J. 1989 Dec;82(12):1579-80 [2595430.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):169-71 [1734224.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2002 Nov;42(5):552-4 [12495110.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):31-5 [12729358.001]
  • [Cites] Indian J Gastroenterol. 1998 Oct-Dec;17(4):156-7 [9795511.001]
  • [Cites] Semin Oncol. 1981 Sep;8(3):313-20 [7280715.001]
  • [Cites] Mayo Clin Proc. 1982 Oct;57(10):634-8 [7121070.001]
  • [Cites] Surg Today. 2000;30(1):98-100 [10648095.001]
  • [Cites] Pediatr Pathol. 1988;8(3):321-9 [3174512.001]
  • [Cites] Diagn Cytopathol. 1989;5(1):14-21 [2656144.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):134-9 [7237380.001]
  • [Cites] Acta Pathol Jpn. 1985 Jul;35(4):989-93 [4072681.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):220 [11961660.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):517-8 [12789944.001]
  • [Cites] Eur J Surg. 1992 Aug;158(8):451-3 [1356488.001]
  • [Cites] Arch Surg. 1990 Nov;125(11):1477-81 [2241560.001]
  • [Cites] APMIS. 1988 Feb;96(2):123-7 [3345257.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):157-60 [7773468.001]
  • [Cites] Cancer. 1975 Jan;35(1):165-75 [1109769.001]
  • [Cites] J Occup Environ Med. 2004 Jan;46(1):84-9 [14724482.001]
  • [Cites] Radiology. 1989 Feb;170(2):333-7 [2643136.001]
  • [Cites] Cancer. 1980 May 1;45(9):2395-9 [7379036.001]
  • [Cites] Z Gastroenterol. 2003 Apr;41(4):329-32 [12695939.001]
  • [Cites] Semin Diagn Pathol. 1991 Nov;8(4):277-89 [1759060.001]
  • [Cites] Am J Clin Pathol. 1981 Nov;76(5):627-35 [7293978.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):192-5 [11884057.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Surgery. 1979 Oct;86(4):556-60 [483165.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Dig Surg. 2000;17(4):323-8 [11053936.001]
  • [Cites] J Clin Pathol. 1993 Sep;46(9):867-8 [8227441.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(5):443-7 [2122588.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):839-49 [15637690.001]
  • [Cites] Eur J Surg Oncol. 1997 Oct;23(5):461-2 [9393582.001]
  • [Cites] Pathol Res Pract. 1986 Dec;181(6):767-73 [2436202.001]
  • [Cites] Arch Pathol Lab Med. 1996 Oct;120(10):959-66 [12046609.001]
  • [Cites] Abdom Imaging. 1998 Sep-Oct;23 (5):502-4 [9841063.001]
  • [Cites] Clin Radiol. 1993 Jul;48(1):66-7 [8370225.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jan;14(1):77-80 [11782579.001]
  • [Cites] J Gastroenterol. 1996 Dec;31(6):868-74 [9027654.001]
  • [Cites] J Obstet Gynaecol Can. 2002 Mar;24(3):246-7 [12196875.001]
  • (PMID = 16547615.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med; 2006 May 15;173(10):1155-60
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
  • BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue.
  • Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet.
  • METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma.
  • FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L).
  • The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%).
  • The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%).
  • SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L).
  • The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%).
  • The AUC for pleural SMRP-differentiating metastasis and mesothelioma was 0.793.
  • INTERPRETATION: We show that SMRPs may be a promising marker for mesothelioma diagnosis when measured either in serum or pleural fluid.
  • The diagnostic value of SMRPs was similar in both types of samples, but pleural fluid SMRPs may better discriminate mesothelioma from pleural metastasis.
  • [MeSH-major] Asbestosis / pathology. Membrane Glycoproteins / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / pathology. Sialoglycoproteins / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease Progression. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Osteopontin. Prognosis. Prospective Studies. Sensitivity and Specificity. Solubility. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456138.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


20. Bandier PC, Hansen A, Thorelius L: [Adenomatoid tumour of the adrenal gland]. Ugeskr Laeger; 2009 Jan 26;171(5):306-8
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumour of the adrenal gland].
  • [Transliterated title] Adenomatoid tumor i binyre.
  • An adenomatoid tumour in the right suprarenal gland was discovered during clinical cancer staging of a 73-year-old woman.
  • Adenomatoid tumours in the suprarenal glands are rare and are most often found incidentally.
  • Differential diagnoses comprise malignant vascular neoplasm or adenocarcinoma.
  • Immunohistochemistry or electron microscopy allows uncomplicated distinction between these tumours.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ugeskr Laeger. 2009 Mar 16;171(12):1015; author reply 1015 [19306484.001]
  • (PMID = 19176156.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


21. Bestard Vallejo JE, Tremps Velázquez E, Blázquez Mañá C, Celma Doménech A, de Torres Ramírez I, Morote Robles J: [Adenomatoid tumour of epididymis: the most common tumour of the paratesticular structures]. Actas Urol Esp; 2008 Jun;32(6):611-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumour of epididymis: the most common tumour of the paratesticular structures].
  • [Transliterated title] Tumor adenomatoide de epididimo: el tumor más frecuente de las estructuras paratesticulares.
  • INTRODUCTION: Paratesticular tumours are rare but generally benign neoplasms, usually treated by local excission.
  • Adenomatoid tumours of epididymis are the most common of these tumours.
  • OBJECTIVES: Analyze paratesticular tumours treated in our center and describe dyagnosis and treatment of adenomatoid tumours of epididymis.
  • MATERIAL AND METHODS: We retrospectively review 8 patients with paratesticular tumours treated from July 1997 to July 2007.
  • RESULTS: Patients median age was 44.1 years (22-69), presenting most of them subacute scrotal tumour with median size by ultrasound of 2.8 cm (1.5-7).
  • All of them were locally extirpated except one with suspicion of a malignant polyorchidism and another one with an apparently intratesticular lesion of great size.
  • Dyagnosis was in 4 cases adenomatoid tumour of epididymis, in two cases fibrous pseudotumour of epididymis, in one case leiomyoma of epididymis and in one case angiolipoma of spermatic cord.
  • Just in one case diagnosed of adenomatoid tumour of epididymis ultrasound confirmed solid tumour suggesting the final dyagnosis.
  • CONCLUSIONS: Adenomatoid tumors of epididymis are rare tumours which may present at any age.
  • Benignity of adenomatoid tumour of epididymis as well as most of the other paratesticular tumours should make local excission the treatment of choice and, when any doubt existed, peroperatory biopsy should be performed.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655344.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 19
  •  go-up   go-down


22. Assaly M, Bongiovanni M, Kumar N, Egger JF, Pelte MF, Genevay M, Finci V, Tschanz E, Pache JC: Cytology of benign multicystic peritoneal mesothelioma in peritoneal washings. Cytopathology; 2008 Aug;19(4):224-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of benign multicystic peritoneal mesothelioma in peritoneal washings.
  • OBJECTIVE: To describe the cytological aspect of peritoneal washings in benign multicystic peritoneal mesothelioma (BMPM).
  • RESULTS: The specimens showed an abundance of monomorphous mesothelial cells devoid of atypia or mitoses.
  • The mesothelial cells were calretinin positive.
  • CONCLUSION: The combination of cytology of the peritoneal washing, histology (cell block and surgical specimen) and clinical history allow differentiation of BMPM from other cystic lesions (cystic lymphangioma and malignant mesothelioma).
  • [MeSH-major] Immunohistochemistry / methods. Mesothelioma, Cystic / pathology. Neoplasms / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Peritoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476992.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N: Malignant mesothelioma. Intern Med J; 2010 Nov;40(11):742-50
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma (MM) is an aggressive tumour that commonly affects the mesothelial surfaces of the pleural and peritoneal cavities, and occasionally, the tunica vaginalis and the pericardium.
  • Formerly a rare tumour, MM is increasing in incidence in Australia due to the heavy nationwide use of asbestos from 1940 until the 1980s.
  • Definitive pathological diagnosis is required and it often requires an experienced pathologist to differentiate MM from other benign or malignant processes.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Mesothelioma / epidemiology. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.
  • (PMID = 20298508.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


24. Limone A, Maier J, Chiantera V, Elezkurtaj S, Foss HD, Schneider A: Laparoscopic excision of a benign peritoneal cystic mesothelioma. Arch Gynecol Obstet; 2010 Mar;281(3):577-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic excision of a benign peritoneal cystic mesothelioma.
  • Benign cystic peritoneal mesothelioma is a rare tumor and most commonly occurs in women in the reproductive age group.
  • We present a rare case of a postmenopausal woman with benign peritoneal cystic mesothelioma removed at laparoscopy.
  • [MeSH-major] Laparoscopy. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669775.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


25. Moore AJ, Parker RJ, Wiggins J: Malignant mesothelioma. Orphanet J Rare Dis; 2008;3:34
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
  • The exact prevalence is unknown but it is estimated that mesotheliomas represent less than 1% of all cancers.
  • Pleural malignant mesothelioma is the most common form of mesothelioma.
  • Mesothelioma is directly attributable to occupational asbestos exposure with a history of exposure in over 90% of cases.
  • There is also evidence that mesothelioma may result from both para-occupational exposure and non-occupational "environmental" exposure.
  • Idiopathic or spontaneous mesothelioma can also occur in the absence of any exposure to asbestos, with a spontaneous rate in humans of around one per million.
  • Distinguishing malignant from benign pleural disease can be challenging.
  • The most helpful CT findings suggesting malignant pleural disease are 1) a circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of > 1 cm and 4) mediastinal pleural involvement.
  • Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care.
  • Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):56-60 [17044196.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:44 [17090323.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005574 [17253564.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):182-7 [17359904.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] Exp Anim. 2007 Apr;56(2):155-9 [17460361.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Radiother Oncol. 2007 Jul;84(1):18-22 [17588698.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1366-74 [17674974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7 [17467922.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] Eur Respir J. 2007 Nov;30(5):1021 [17978160.001]
  • [Cites] Occup Med (Lond). 2007 Dec;57(8):564-8 [17675661.001]
  • [Cites] Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272 [18154821.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Ann Thorac Surg. 2008 Mar;85(3):1049-55 [18291195.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):397-401 [18318582.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 [18329481.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Curr Opin Pulm Med. 2008 Jul;14(4):303-9 [18520263.001]
  • [Cites] Regul Toxicol Pharmacol. 2008 Oct;52(1 Suppl):S223-31 [18022298.001]
  • [Cites] Occup Med (Lond). 2005 Mar;55(2):79-87 [15757980.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):143-6 [10925221.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):251-7 [12052665.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):111-21 [12399121.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16 [12573747.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii29-38 [12728148.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):321-32 [14571437.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Thorax. 2004 Feb;59(2):144-8 [14760156.001]
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(1):CD002916 [14973997.001]
  • [Cites] Int J Occup Environ Health. 2004 Jan-Mar;10(1):26-39 [15070023.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 15;170(4):377-82 [15142871.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1406-12 [15319247.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66 [15451223.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Acta Clin Belg. 1989;44(3):199-201 [2816228.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):433-8 [1995528.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Nov;3(6):315-7 [1720658.001]
  • [Cites] Australas Radiol. 1994 Aug;38(3):212-4 [7524472.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):535-9 [7776771.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):370-4 [7790544.001]
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(5):317-8 [8580058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Eur Respir J. 1996 Jun;9(6):1206-10 [8804939.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6 [8813257.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):162-6 [9237066.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Thorax. 1997 Aug;52 Suppl 3:S52-7 [9381428.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):269-73 [9602260.001]
  • [Cites] Respir Med. 1998 Apr;92(4):691-2 [9659538.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4505-9 [9788590.001]
  • [Cites] Radiology. 1999 Jan;210(1):277-81 [9885620.001]
  • [Cites] Occup Environ Med. 1999 Jan;56(1):51-8 [10341747.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):587-93 [15668716.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):314-20 [15780570.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S37-40 [15950799.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003880 [16856023.001]
  • (PMID = 19099560.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2652430
  •  go-up   go-down


26. Leaha C, Opris I, Macé P, Resch B, Sabourin JC: [Cystic adenomatoid tumor of the uterus]. Ann Pathol; 2009 Apr;29(2):134-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic adenomatoid tumor of the uterus].
  • [Transliterated title] Tumeur adénomatoïde kystique utérine.
  • Adenomatoid tumors are benign neoplasms of mesothelial origin, which involve the feminine and masculine genital tracts.
  • Our study presents an adenomatoid tumour, of cystic shape, which enables discussion of the histogenesis of this tumour and enlightenment of differential diagnoses which can at times result in an incorrect malignant diagnosis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364588.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


27. Shen J, Pinkus GS, Deshpande V, Cibas ES: Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol; 2009 Apr;131(4):516-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
  • We compared the effectiveness of epithelial membrane antigen (EMA) with 2 newly described markers, X-linked inhibitor of apoptosis protein (XIAP) and an isoform of glucose transporter (GLUT-1), in the distinction between malignant mesothelioma (MM) and benign effusion (BE) in body cavity fluids.
  • [MeSH-major] Glucose Transporter Type 1 / biosynthesis. Mesothelioma / diagnosis. Mucin-1 / biosynthesis. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / diagnosis. X-Linked Inhibitor of Apoptosis Protein / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289587.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Mucin-1; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


28. Pinto V, Rossi AC, Fiore MG, D'Addario V, Cicinelli E: Laparoscopic diagnosis and treatment of pelvic benign multicystic mesothelioma associated with high CA19.9 serum concentration. J Minim Invasive Gynecol; 2010 Mar-Apr;17(2):252-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic diagnosis and treatment of pelvic benign multicystic mesothelioma associated with high CA19.9 serum concentration.
  • We report a case of benign multicystic mesothelioma in a 20-year-old woman referred because of amenorrhea.
  • Tumor serum markers revealed an increase in CA19.9.
  • Microscopically, cystic lesions showed mesothelium-lined cystic spaces surrounded by a delicate thin fibrovascular wall.
  • With immunohistochemistry, the tumor cells were strongly positive for cytokeratin and calretinin.
  • These aspects were suggestive of benign multicystic mesothelioma.
  • Electron microscopy confirmed the mesothelial nature of this tumor.
  • The association between benign multicystic mesothelioma and increased CA19.9 serum concentration has been described only once, in a man.
  • To our knowledge, this is the second case of benign multicystic mesothelioma associated with increased CA19.9 serum concentration and the first diagnosed in a woman.
  • In the present case, a minimally invasive laparoscopic approach enabled not only histologic diagnosis of benign multicystic mesothelioma but also its surgical treatment.
  • Although benign multicystic mesothelioma is a rare pathologic entity, it is important that sonologists include it in the differential diagnosis of diseases that manifest with ascites.
  • Furthermore, all surgeons should be aware of the macroscopic and laparoscopic appearance of the lesion, and its generally benign course.
  • [MeSH-major] CA-19-9 Antigen / blood. Laparoscopy. Mesothelioma, Cystic / pathology. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20226419.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


29. Reid A, de Klerk N, Ambrosini G, Olsen N, Pang SC, Musk AW: The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup Environ Med; 2005 Oct;62(10):665-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis.
  • AIMS: To examine the hypothesis that people with benign pleural disease or asbestosis have an increased risk of malignant mesothelioma beyond that attributable to their degree of asbestos exposure.
  • The first plain chest radiograph taken at the time of recruitment into the cancer prevention programme was read for evidence of benign pleural disease and asbestosis, using the UICC classification.
  • Cox proportional hazards modelling was used to relate benign pleural disease, asbestosis, asbestos exposure, and mesothelioma.
  • RESULTS: Between 1990 and 2002, there were 76 cases of mesothelioma (56 of the pleura and 20 of the peritoneum).
  • Cases had more radiographic evidence of (all) benign pleural disease, pleural thickening, blunt/obliterated costophrenic angle, and asbestosis than non-cases.
  • Adjusting for time since first exposure (log years), cumulative exposure (log f/ml-years), and age at the start of the programme, pleural thickening (OR = 3.1, 95% CI 1.2 to 7.6) and asbestosis (OR = 3.3, 95% CI 1.3 to 8.6) were associated with an increased risk of peritoneal mesothelioma.
  • There was no increased risk for pleural mesothelioma.
  • CONCLUSION: The presence of benign pleural disease, in particular pleural thickening, and asbestosis appears to increase the risk of mesothelioma of the peritoneum, but not of the pleura beyond that attributable to indices of asbestos exposure in this cohort of subjects exposed to crocidolite.
  • [MeSH-major] Asbestosis / complications. Lung Neoplasms / etiology. Mesothelioma / etiology. Occupational Exposure. Pleural Diseases / complications


30. Pitta X, Andreadis E, Ekonomou A, Papachristodoulou A, Tziouvaras C, Papapaulou L, Sapidis N, Chrisidis T: Benign multicystic peritoneal mesothelioma: a case report. J Med Case Rep; 2010;4:385

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: a case report.
  • INTRODUCTION: We report the case of a patient with a benign multicystic peritoneal mesothelioma and describe its appearance on computed tomography scans and ultrasonography, in correlation with gross clinical and pathological findings.
  • Abdominal ultrasonography and computed tomography demonstrated the presence of a large cystic mass in her left upper abdomen, adjacent to her left hemidiaphragm.
  • Pathological analysis showed a benign multicystic peritoneal mesothelioma.
  • CONCLUSIONS: Benign multicystic peritoneal mesothelioma is a rare lesion with a non-specific appearance on imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114811.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2999614
  •  go-up   go-down


31. Coskun A, Guven MA, Ozdemir O, Cirakli H, Karakus S: Benign cystic mesothelioma presenting as a huge pelvic mass--a case report. Eur J Gynaecol Oncol; 2006;27(6):621-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma presenting as a huge pelvic mass--a case report.
  • Benign cystic mesothelioma is an extremely rare peritoneal tumor.
  • It is reported in women of childbearing [corrected] age but also in males and needs a careful [corrected] differential diagnosis between benign and malign neoplasia to choose the most [corrected] adeguate therapy.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2007;28(1):3
  • (PMID = 17290598.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Saad S, Brockmann M, Maegele M: Benign peritoneal multicystic mesothelioma diagnosed and treated by laparoscopic surgery. J Laparoendosc Adv Surg Tech A; 2007 Oct;17(5):649-52
Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign peritoneal multicystic mesothelioma diagnosed and treated by laparoscopic surgery.
  • Benign cystic mesothelioma is a rare pathology predominantly encountered in females.
  • The increased use of laparoscopy for abdominal pain, particularly in female patients, implies that surgeons are aware of the macro- and laparoscopic presentation of this tumor for adequate diagnosis and therapy.
  • In this paper, we present the case of a young woman with benign multicystic mesothelioma in which only laparoscopy led to the appropriate diagnosis.
  • Subsequently, the tumor was removed by laparoscopic surgery.
  • [MeSH-major] Laparoscopy / methods. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907980.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Tangjitgamol S, Erlichman J, Northrup H, Malpica A, Wang X, Lee E, Kavanagh JJ: Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1101-7
Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature review.
  • We report on benign multicystic peritoneal mesothelioma in two siblings whose family had a history of multiple familial diseases including diverticulosis.
  • After a genetic evaluation and a chromosomal analysis, we were not able to identify a specific genetic cause of the family's pattern of disease.
  • [MeSH-major] Mesothelioma, Cystic / genetics. Mesothelioma, Cystic / therapy. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343188.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 29
  •  go-up   go-down


34. Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M, Masjedi MR: The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med; 2008 Apr;132(4):694-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
  • CONTEXT: The differentiation of benign mesothelial proliferations from malignant mesotheliomas may be difficult, especially when evaluating small specimens from pleural biopsies.
  • OBJECTIVE: To explore the potential value of 2 proliferative cell markers, Ki-67 and restrictedly expressed proliferation-associated protein 86 kDa (repp86), in distinguishing between malignant mesothelioma (MM) and benign reactive mesothelial hyperplasia (MH).
  • DESIGN: Thirty-six cases of MM from 26 men and 10 women with a mean age of 62.9 years (range, 36-80 years) and 22 cases of benign reactive MH from 14 male and 8 female patients with a mean age of 51.5 years (range, 15- 88 years) were included in this study.
  • RESULTS: The mean labeling indexes for Ki-67 in MM and benign reactive MH were 24.6% (range, 1%-66%) and 6.23% (range, 0%-25%), respectively.
  • The mean labeling indexes for repp86 in MM and benign reactive MH were 26.3% (range, 0%-50%) and 3.26% (range, 0%- 21%), respectively.
  • The average proliferative cell count was significantly higher in MM compared with benign reactive MH (P < .001).
  • Furthermore, both markers showed a significant correlation in their expression in MM and benign reactive MH (r = 77.5, P < .001).
  • CONCLUSIONS: Used in combination, Ki-67 and repp86 appear to be useful markers in differentiating MM from benign reactive MH.
  • [MeSH-major] Epithelium / metabolism. Ki-67 Antigen / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Neoplasms, Mesothelial / diagnosis. Neoplasms, Mesothelial / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Hyperplasia / pathology. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384222.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / SND1 protein, human
  •  go-up   go-down


35. Terry NE, Fowler CL: Benign cystic mesothelioma in a child. J Pediatr Surg; 2009 May;44(5):e9-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma in a child.
  • Grossly, it resembled lymphangioma; however, histopathologic diagnosis was benign cystic mesothelioma (BCM), an entity that presents mainly in women of childbearing age.
  • He also underwent resection of a congenital cystic adenomatoid malformation of the right lung.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cystic Adenomatoid Malformation of Lung, Congenital / surgery. Diagnosis, Differential. Dyspnea / etiology. Humans. Infant. Lymphangioma / diagnosis. Male. Neoplasm Recurrence, Local / surgery. Pleural Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433159.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G: Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol; 2010 Jul 10;28(20):3316-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
  • PURPOSE: In malignant mesothelioma (MM), radiologic assessment of disease status is difficult.
  • Both soluble mesothelin-related peptide (SMRP) and osteopontin (OP) have utility in distinguishing MM from benign pleural disease.
  • We evaluated whether SMRP and OP also correlated with the disease course of MM.
  • Radiologic tests across time periods showing disease progression, stability, or shrinkage were compared with corresponding changes in SMRP/OP levels.
  • At study entry, 37 of 41 patients had measurable disease, of whom 92% (34 of 37) had elevated baseline SMRP levels; four of 41 patients had no evidence of recurrence and each had normal baseline SMRP levels.
  • In 21 patients receiving systemic therapy, percentage change in SMRP more than 10% correlated with the radiologic assessment by a trained thoracic radiologist (P < .001), by formal Response Evaluation Criteria in Solid Tumors (RECIST; P = .008), or by modified RECIST (P < .001).
  • Rising SMRP was observed in all patients with radiologic disease progression.
  • CONCLUSION: Percentage changes in SMRP levels, but not changes in OP levels, are a potentially useful marker of disease course.
  • These findings should be validated prospectively for a role as an objective adjunctive measure of disease course in both clinical trials and clinical practice.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Peritoneal Neoplasms / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. GPI-Linked Proteins. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20498407.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


37. O'Connor DB, Beddy D, Aremu MA: Benign cystic mesothelioma of the appendix presenting in a woman: a case report. J Med Case Rep; 2010;4:394

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma of the appendix presenting in a woman: a case report.
  • INTRODUCTION: Benign cystic mesothelioma or peritoneal inclusion cysts are rare benign abdominal tumors usually occurring in females of reproductive age.
  • They are commonly associated with pelvic inflammatory disease, endometriosis, or ovarian cysts.
  • We report what is, to the best of our knowledge, the first case of a benign cystic mesothelioma complicating a presentation of acute appendicitis.
  • Histology revealed benign cystic mesothelioma.
  • CONCLUSION: We report what is, to the best of our knowledge, the first case of a benign cystic mesothelioma arising from the appendix and complicating a presentation of acute appendicitis.
  • This is a benign pathology, but recurrences are not uncommon.
  • Benign cystic mesothelioma should be included in the differential when investigating pelvic masses or abscesses associated with either appendicitis or pelvic inflammatory disease in women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129176.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3003679
  •  go-up   go-down


38. McCaffrey JC, Foo FJ, Dalal N, Siddiqui KH: Benign multicystic peritoneal mesothelioma associated with hydronephrosis and colovesical fistula formation: report of a case. Tumori; 2009 Nov-Dec;95(6):808-10
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma associated with hydronephrosis and colovesical fistula formation: report of a case.
  • Mesotheliomas usually arise from the pleura and are malignant.
  • We report an unusual case of benign peritoneal mesothelioma presenting in a 59-year-old woman.
  • The disease resulted in bilateral hydronephrosis, colovesical fistula formation, recurrent small bowel obstruction and chronic abdominal pain.
  • [MeSH-major] Hydronephrosis / etiology. Intestinal Fistula / etiology. Mesothelioma / complications. Peritoneal Neoplasms / complications
  • [MeSH-minor] Abdominal Pain / etiology. Chronic Disease. Female. Humans. Intestinal Obstruction / etiology. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210248.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


39. Dueñas García OF, Kerckoff Villanueva H, Rico Olvera H, Lira Plascencia J: [Benign peritoneal cystic mesothelioma as differential diagnose of an ovarian dependant tumor. Case report and review of the literature]. Ginecol Obstet Mex; 2007 Feb;75(2):111-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign peritoneal cystic mesothelioma as differential diagnose of an ovarian dependant tumor. Case report and review of the literature].
  • [Transliterated title] Mesotelioma quistico peritoneal benigno como diagnóstico diferencial de tumor dependiente del ovario. Comunicación de un caso y revisión bibliográfica.
  • Benign cystic mesothelioma is an uncommon lesion of the peritoneum, occurring predominantly in women of reproductive age.
  • The present case is a multitreated perimenopausal woman with lower urinary tract symptoms without clinical improvement despite the treatment, and pelvic pain with physical findings and radiology studies of a probable ovarian mass dependant tumoration, requiring protocolized exploratory laparotomy, finding a benign cystic mesothelioma.
  • Despite the low incidence of this tumoration the gynecologist must be familiar with this disease, because of the high recurrence.
  • [MeSH-major] Mesothelioma, Cystic / pathology. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542260.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


40. Llarena Ibarguren R, Rodríguez JG, Olano Grasa I, Azurmendi Arín I, Cantón Aller E, Pertusa Peña C: [Adenomatoid tumor of the epididymis. Report of five cases]. Arch Esp Urol; 2008 Sep;61(7):831-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis. Report of five cases].
  • [Transliterated title] Tumor adenomatoide epididimario. Aportación de 5 casos.
  • OBJECTIVE: Adenomatoid tumor of the epididymis is unfrequent, benign, with no malignant outcomes described.
  • METHODS: We report five cases, with patient's ages varying from 31 to 76 years, and tumor sizes from 6 to 30 mm.
  • Pathology confirmed the benign adenomatoid character in all cases.
  • CONCLUSIONS: Despite the clinical, ultrasound and physical examination findings suggest the localization in the epididymis and its benign character, surgical exploration is mandatory with surgical excision of the paratesticular mass.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972922.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Dejmek A: CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma. Acta Cytol; 2008 Sep-Oct;52(5):579-83
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
  • OBJECTIVE: To test the performance of CK5/6 for the differentiation between mesothelioma, adenocarcinoma and benign mesothelia/proliferations in effusion cytology.
  • STUDY DESIGN: CKS/6 immunocytochemistry was applied to ethanol-fixed cytospin preparations from 74 benign and malignant effusions.
  • RESULTS: Reactivity was seen in 7 of 8 mesotheliomas and in 9 of 11 benign mesothelial proliferations but also in 11 of l7 pulmonary adenocarcinomas and in 12 of 31 adenocarcinomas of nonpulmonary origin.
  • The high reactivity rate in pulmonary adenocarcinomas disagrees with the results obtained with histologic sections from solid tumor tissue, and CK5/6 seems to be of very limited value as an additional marker in effusion cytology.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Lung Neoplasms / metabolism. Mesothelioma / metabolism. Pleural Effusion / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833821.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-5; 0 / Keratin-6
  •  go-up   go-down


42. Aziz F: Radiological Findings in a case of Advance staged Mesothelioma. J Thorac Dis; 2009 Dec;1(1):46-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological Findings in a case of Advance staged Mesothelioma.
  • Chest X Ray is the initial screening test for the mesothelioma like all other the chest diseases.
  • Certain CT features help differentiate benign from malignant processes.
  • This short article highlights the salient CT appearance of mesothelioma; the most common pleural tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22263002.001).
  • [ISSN] 2072-1439
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3256484
  • [Keywords] NOTNLM ; Advance staged Mesothelioma / Radiological Findings
  •  go-up   go-down


43. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer; 2008 May 6;98(9):1562-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
  • MUC1/EMA expression has been observed in the majority of epithelioid mesotheliomas.
  • However, little is known of the characteristics of MUC1/EMA in mesothelioma.
  • Herein, we studied the cell surface and soluble expression of the MUC1/EMA glycoprotein, and determined the mRNA and genomic expression profiles in mesothelioma.
  • MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells.
  • Seven of 9 mesothelioma samples expressed MUC1-secreted mRNA isoform in addition to the archetypal MUC1/transmembrane form.
  • CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease.
  • CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma.
  • Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mucin-1 / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):102-5 [11249725.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):166-71 [12115565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8 [12620150.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):347-54 [3899155.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):755-61 [7679050.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5847s-5851s [7493358.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:88-99 [9422093.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:111-7 [9422095.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):156-9 [15690334.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Tumour Biol. 2000 Jul-Aug;21(4):197-210 [10867613.001]
  • (PMID = 18454162.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2391110
  •  go-up   go-down


44. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med; 2009 Aug;133(8):1317-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
  • CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose.
  • DATA SOURCES: A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006).
  • CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM.
  • The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653732.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


45. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med; 2009 Jul;15(4):366-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and pleural fluid biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Malignant mesothelioma is an asbestos-induced, aggressive tumour.
  • In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring.
  • With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field.
  • The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease.
  • The assay has a high level of specificity relative to benign lung and pleural conditions and is positive in 10-15% of other malignancies.
  • SUMMARY: To date, soluble mesothelin remains the best available biomarker for malignant mesothelioma.
  • However, a lack of sensitivity for early-stage disease and for all malignant mesothelioma histologies provides motivation for the search of novel malignant mesothelioma biomarkers with greater sensitivity, especially for very early disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417672.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  • [Number-of-references] 52
  •  go-up   go-down


46. Scherpereel A, French Speaking Society for Chest Medicine (SPLF) Experts Group: Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med; 2007 Jun;101(6):1265-76
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
  • Previously considered as a rare tumor, malignant pleural mesothelioma (MPM) has become a very important public health issue.
  • In fact, MPM is a tumor with a poor survival, and its incidence is expected to continue to increase for at least the next 10 years.
  • The diagnosis of MPM may be difficult because of differential diagnosis such as pleural benign disease induced by asbestos exposure or pleural metastasis of adenocarcinoma.
  • Management of patients with MPM also remains complicated because they are often referred for evaluation late in the evolution of the disease.
  • Between April 2005 and January 2006, the French Speaking Society for Chest Medicine (SPLF), in collaboration with other French scientific societies, brought together experts on mesothelioma to draw up recommendations in order to provide clinicians with clear, concise, up-to-date guidelines on management of MPM, presented in this report.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17137779.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 11
  •  go-up   go-down


47. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C: Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res; 2007 Jul 15;13(14):4191-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
  • PURPOSE: CD26 is a 110-kDa cell surface antigen with a role in tumor development.
  • In this report, we show that CD26 is highly expressed on the cell surface of malignant mesothelioma and that a newly developed humanized anti-CD26 monoclonal antibody (mAb) has an inhibitory effect on malignant mesothelioma cells in both in vitro and in vivo experiments.
  • EXPERIMENTAL DESIGN: Using immunohistochemistry, 12 patients' surgical specimens consisting of seven malignant mesothelioma, three reactive mesothelial cells, and two adenomatoid tumors were evaluated for expression of CD26.
  • The effects of CD26 on malignant mesothelioma cells were assessed in the presence of transfection of CD26-expressing plasmid, humanized anti-CD26 mAb, or small interfering RNA against CD26.
  • The in vivo growth inhibitory effect of humanized anti-CD26 mAb was assessed in human malignant mesothelioma cell mouse xenograft models.
  • RESULTS: In surgical specimens, CD26 is highly expressed in malignant mesothelioma but not in benign mesothelial tissues.
  • Moreover, our in vitro data indicate that humanized anti-CD26 mAb induces cell lysis of malignant mesothelioma cells via antibody-dependent cell-mediated cytotoxicity in addition to its direct anti-tumor effect via p27(kip1) accumulation.
  • In vivo experiments with mouse xenograft models involving human malignant mesothelioma cells show that humanized anti-CD26 mAb treatment drastically inhibits tumor growth in tumor-bearing mice, resulting in enhanced survival.
  • CONCLUSIONS: Our data strongly suggest that humanized anti-CD26 mAb treatment may have potential clinical use as a novel cancer therapeutic agent in CD26-positive malignant mesothelioma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Dipeptidyl Peptidase 4 / immunology. Lung Neoplasms / immunology. Mesothelioma / immunology
  • [MeSH-minor] Antigens, CD / genetics. Antigens, CD / immunology. Humans. Immunity, Cellular. Immunohistochemistry. Immunotherapy. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634548.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  •  go-up   go-down


48. Alvarez Maestro M, Tur Gonzalez R, Alonso Dorrego JM, Jesus De la Peña Barthel J, Nistal Martin De Serrano M: [Adenomatoid tumors of the epididymis and testicle: report of 9 cases and bibliographic review]. Arch Esp Urol; 2009 Mar;62(2):137-41
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumors of the epididymis and testicle: report of 9 cases and bibliographic review].
  • [Transliterated title] Tumor adenomatoide de epidídimo intratesticular: A proposito de nueve casos y revisión de la literatura.
  • BACKGROUND: To report the cases of adenomatoid tumors seen at Hospital Universitario La Paz in the last 15 years.
  • METHODS: A clinical, pathological, and surgical study was conducted of males with testicular or paratesticular tumors with a histological report of adenomatoid tumor.
  • RESULTS: Among the nine cases studied, seven had paratesticular and two intratesticular adenomatoid tumors.
  • Treatment of choice was mass removal for epididymal tumors and orchidectomy for intratesticular tumors.
  • CONCLUSIONS: Adenomatoid tumors are uncommon benign neoplasms of a possible mesothelial origin.
  • Because of their benign nature, the treatment of choice is local excision (conservative surgery), but orchidectomy was performed in two cases due to tumor location.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male. Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448282.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


49. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and functional imaging of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor that arises from the pleura and frequently extends to adjacent structures.
  • Major findings include nodular pleural thickening, unilateral pleural effusion, and tumor invasion of adjacent structures.
  • Perfusion CT can evaluate the microvasculature of tumors, while its disadvantages, such as high radiation exposure or side effects from iodinated contrast, limit its use in both research and clinical settings.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion MRI is the most promising technique for the assessment of the tumor microvasculature.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • An initial report on PET/CT imaging of MPM has shown increased accuracy of overall staging, improving the assessment of tumor resectability.
  • PET/CT seems to be superior to other imaging modalities in detecting more extensive disease involvement, and identifying unsuspected occult distant metastases.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954021.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 61
  •  go-up   go-down


50. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg; 2008 Jan;85(1):265-72; discussion 272
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
  • BACKGROUND: Soluble mesothelin-related peptide (SMRP) is a potential marker for malignant pleural mesothelioma (MPM), which may be useful for screening high-risk asbestos-exposed individuals.
  • METHODS: We evaluated SMRP in serum from MPM patients (n = 90), lung cancer patients (n = 170), age and tobacco-matched asbestos-exposed individuals (n = 66), and in MPM pleural effusions (n = 45), benign effusions (n = 30), and non-MPM effusions (n = 20) using the MesoMark enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • The MPM pleural effusion SMRP was significantly higher than benign or other non-MPM pleural effusions (65.57 +/- 11.33 nM vs 27.46 +/- 11.25 nM [p = 0.003] and 18.99 +/- 7.48 nM [p = 0.044], respectively).
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Effusion, Malignant / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Area Under Curve. Asbestosis / blood. Asbestosis / complications. Asbestosis / mortality. Asbestosis / pathology. Case-Control Studies. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154821.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


51. Chiappino G: [Mesothelioma: the aetiological role of ultrathin fibres and repercussions on prevention and medical legal evaluation]. Med Lav; 2005 Jan-Feb;96(1):3-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesothelioma: the aetiological role of ultrathin fibres and repercussions on prevention and medical legal evaluation].
  • [Transliterated title] Mesotelioma: il ruolo delle fibre ultrafini e conseguenti riflessi in campo preventivo e medico legale.
  • BACKGROUND: Mesothelioma has until now been considered to be a manifestation, occurring in the pleura and/or peritoneum, of the carcinogenic action of the total burden of inhaled asbestos fibres, in the same way as lung cancer.
  • Because of the pathogenic potential of very low exposure levels, the fact that the onset of the neoplasm always occurs in the parietal pleura, and the absence of any synergism with smoking, which is typical in the case of carcinoma, it was suspected that aetiopathogenetic differences existed but the reasons for such differences still could not be explained.
  • In the past experimental results indicated the oncogenicity of very thin fibres but mesothelioma in practice was not exclusively linked to this specific dimensional size class.
  • OBJECTIVES: The paper proposes to take full advantage of the significant knowledge that must emerged from research carried out in recent years and use this knowledge to reconstruct the mosaic of the aetiopathogenesis of mesothelioma.
  • RESULTS: The most important knowledge that must today be taken as certain is the fact that mesothelioma is not caused, as is the case for asbestosis, by all the fibres that are inhaled but only by the ultrathin fraction of these fibres, having diameter of 0.2 microm and length of only a few microm.
  • Only fibres of this class of size can cross the pulmonary-pleural barrier and are, therefore, the causal agent of mesothelioma and other benign pleural manifestations (plaques).
  • Due to their shape, the fibres cannot easily be absorbed into the stoma via the lymphatic flow and so remain clustered for an indefinite period of time among the mesothelial cells that surround the stoma.
  • The concentration of ultrathin fibres in punctiform areas of the parietal pleura and the extremely long biopersistence of the amphiboles now finally explain how very low exposures can cause mesothelioma in susceptible subjects and why the neoplasm always occurs on the parietal pleura.
  • CONCLUSIONS: In medical-legal assessments of cases of mesothelioma the etiological importance of the ultrathin fraction of fibres means that any assumption of the disease being avoidable must be discarded, at least up to the second half of the 1980s because until then this class of fibres, which today must be considered as the true causal agent of the neoplasm, was not visible under the optical microscope, nor could such fibres be measured or eliminated from the atmosphere of working environments.
  • [MeSH-major] Mesothelioma / etiology. Mesothelioma / prevention & control. Pleural Neoplasms / etiology. Pleural Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Lav. 2005 May-Jun;96(3):262; author reply 264-6 [16273846.001]
  • [CommentIn] Med Lav. 2005 May-Jun;96(3):263-4; author reply 264-6 [16273847.001]
  • (PMID = 15847104.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Mineral Fibers; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  •  go-up   go-down


52. Cuartas JE, Maheshwari AV, Qadir R, Cooper AJ, Robinson PG, Pitcher JD Jr: Benign multicystic peritoneal mesothelioma in a cesarean-section scar presenting as a fungating mass. Int J Clin Oncol; 2008 Jun;13(3):275-8
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma in a cesarean-section scar presenting as a fungating mass.
  • We report a case of a benign multicystic mesothelioma, which presented as a fungating mass through the anterior abdominal wall and arose in a cesarean-section scar without direct peritoneal involvement.
  • Although a history of previous abdominal surgery has been reported in a patient with benign multicystic mesothelioma, to the best of our knowledge, there is no report of a benign multicystic mesothelioma arising in a cesarean-section scar or presentation as a fungating skin mass.
  • A pertinent review of the literature on benign multicystic mesothelioma is also presented.
  • [MeSH-major] Cesarean Section / adverse effects. Cicatrix / pathology. Mesothelioma, Cystic / pathology. Peritoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 1999 Sep;84(4):533-4 [10468779.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):31-5 [12729358.001]
  • [Cites] J Korean Med Sci. 1999 Apr;14(2):217-9 [10331572.001]
  • [Cites] Surg Today. 2000;30(1):98-100 [10648095.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Jun;93(3):267-8 [16687143.001]
  • [Cites] Histopathology. 1996 Oct;29(4):375-7 [8910046.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):517-8 [12789944.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):619-22 [10800393.001]
  • [Cites] Cleve Clin Q. 1986 Spring;53(1):109-14 [3708838.001]
  • [Cites] Histopathology. 1995 Nov;27(5):479-81 [8575742.001]
  • [Cites] Am J Surg Pathol. 1988 Oct;12(10):737-46 [3421410.001]
  • [Cites] S Afr Med J. 1981 Jan 17;59(3):85-6 [7466509.001]
  • [Cites] Radiology. 1989 Feb;170(2):333-7 [2643136.001]
  • [Cites] Cancer. 1980 May 1;45(9):2395-9 [7379036.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 1999 May;34(5):472-4 [10231425.001]
  • [Cites] J Clin Gastroenterol. 1997 Jun;24(4):276-9 [9252860.001]
  • [Cites] World J Gastroenterol. 2006 Sep 21;12(35):5739-42 [17007034.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1101-7 [16343188.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14 (4):375-8 [2181883.001]
  • [Cites] Obstet Gynecol Surv. 1989 Feb;44(2):89-95 [2915855.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] World J Surg. 2006 Apr;30(4):560-6 [16547615.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jan;14(1):77-80 [11782579.001]
  • [Cites] Pediatr Pathol. 1985;4(3-4):291-302 [3915088.001]
  • (PMID = 18553241.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Gill RR, Gerbaudo VH, Jacobson FL, Trotman-Dickenson B, Matsuoka S, Hunsaker A, Sugarbaker DJ, Hatabu H: MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin N Am; 2008 May;16(2):319-39, x
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of benign and malignant pleural disease.
  • Knowledge of MR imaging appearance of pleural diseases, including pleural effusions and empyema, benign and malignant pleural tumors, and especially mesothelioma, helps guide treatment decisions and surgical planning.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474335.001).
  • [ISSN] 1064-9689
  • [Journal-full-title] Magnetic resonance imaging clinics of North America
  • [ISO-abbreviation] Magn Reson Imaging Clin N Am
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA116271; United States / NCI NIH HHS / CA / R21CA116271-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


54. Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch; 2007 Apr;450(4):455-61
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
  • Cytology allows the diagnosis of malignant mesothelioma (MM) from effusions with high specificity but low sensitivity.
  • HA was analysed in patients with histologically confirmed MM (n=162), adenocarcinoma or other malignant tumours (n=100) and in 90 patients with benign pleural diseases.
  • [MeSH-major] Hyaluronic Acid / analysis. Mesothelioma / diagnosis. Pleural Effusion / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 1977 May 2;76(3):357-61 [870264.001]
  • [Cites] Eur Respir J. 2004 Dec;24(6):1000-6 [15572545.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Jpn J Clin Oncol. 1997 Oct;27(5):293-7 [9390204.001]
  • [Cites] Arch Geschwulstforsch. 1985;55(4):259-64 [4037997.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):405-10 [11018693.001]
  • [Cites] Chest. 1988 Nov;94(5):1037-9 [3180855.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):68-73 [2731122.001]
  • [Cites] Eur Respir J. 2003 Mar;21(3):539-44 [12662014.001]
  • [Cites] Diagn Cytopathol. 1992;8(4):333-41 [1638933.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):445-7; discussion 448 [2635926.001]
  • [Cites] Eur Respir J. 1990 Oct;3(9):985-6 [2289567.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1406-10 [8111707.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Cancer. 1991 May 1;67(9):2410-4 [2013045.001]
  • [Cites] Thorax. 2003 Sep;58(9):809-13 [12947146.001]
  • (PMID = 17377812.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Azure Stains; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


55. Wilkinson L, De P, Bloxham C: Mesothelial reaction in longstanding Crohn's ileitis simulating papillary mesothelioma. J Clin Pathol; 2008 Oct;61(10):1119-21
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial reaction in longstanding Crohn's ileitis simulating papillary mesothelioma.
  • Intestinal and extraintestinal complications of Crohn's disease are well documented.
  • A rare and unusually florid mesothelial reaction in the surrounding small bowel serosa of a patient with a 2-year history of Crohn's ileitis is described.
  • The peritoneal surface of the ileal resection specimen displayed exuberant tubulo-papillary formations of the mesothelium, with superficial invasion of the underlying stroma.
  • The case demonstrates the well-recognised difficult differential diagnosis between a benign mesothelial proliferation and malignant mesothelioma in a novel clinical setting, and the diversity of the extramural manifestations of Crohn's disease.
  • [MeSH-major] Abdominal Neoplasms / pathology. Crohn Disease / pathology. Ileitis / pathology. Ileum / pathology. Mesothelioma / pathology

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820098.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. González Resina R, Carranza Carranza A, Congregado Córdoba J, Conde Sánchez JM, Congregado Ruiz CB, Medina López R: [Paratesticular adenomatoid tumor: a report of nine cases]. Actas Urol Esp; 2010 Jan;34(1):95-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular adenomatoid tumor: a report of nine cases].
  • [Transliterated title] Tumor adenomatoide paratesticular: una serie de nueve casos.
  • INTRODUCTION: Paratesticular tumors are rare.
  • Most of them are benign, and adenomatoid tumors are most common.
  • These tumors sometimes infiltrate the testicular parenchyma and require differential diagnosis with malignant tumors.
  • MATERIALS AND METHODS: A retrospective study of nine patients with paratesticular adenomatoid tumors seen during a nine-year period (2000-2008) is reported.
  • The tumor most commonly occurred as a small, usually oval, nodule in the tail of epididymis.
  • Our series included a case each of intraparenchymal tumor of the testis and tumor of the tunica vaginalis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis / pathology. Genital Neoplasms, Male / pathology
  • [MeSH-minor] Adult. Calbindin 2. Diagnosis, Differential. Humans. Keratins / analysis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Retrospective Studies. S100 Calcium Binding Protein G / analysis. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223139.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  • [Number-of-references] 13
  •  go-up   go-down


57. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


58. de Keizer B, Arsos G, Smit JW, Lam MG, Rinkes IH, Goldschmeding R, van Isselt JW: I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer. Thyroid; 2008 Mar;18(3):369-71
Genetic Alliance. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer.
  • We report a case of focal I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Iodine Radioisotopes. Mesothelioma, Cystic / radionuclide imaging. Peritoneal Neoplasms / radionuclide imaging. Thyroid Nodule / radionuclide imaging. Tomography, Emission-Computed, Single-Photon / adverse effects

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298317.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


59. Lehwald N, Cupisti K, Baldus SE, Kröpil P, Schulte Am Esch J 2nd, Eisenberger CF, Knoefel WT: Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series. J Med Case Rep; 2010;4:402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series.
  • Pathology revealed a benign multicystic mesothelioma.
  • CONCLUSION: Partial pancreaticoduodenectomy is usually performed for ductal adenocarcinomas, neuroendocrine tumors or chronic pancreatitis.
  • Benign multicystic mesothelioma is a very rare tumor that originates from the peritoneum.
  • Although it demonstrates a benign clinical behaviour, it frequently recurs after resection.
  • Adenomyoma of the bile duct or ampullary region is a very unusual, benign, localized lesion characterized by adenomyomatous hyperplasia.
  • Undifferentiated carcinoma, sarcomatoid variant, is an aggressive tumor and is characterized by spindle cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(1):98-100 [10648095.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):530-6 [12808057.001]
  • [Cites] Surg Today. 2008;38(1):85-9 [18085373.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Pancreas. 2005 Oct;31(3):291-2 [16163064.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):547-50 [7550871.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Am J Obstet Gynecol. 1983 Feb 1;145(3):355-9 [6824025.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • (PMID = 21143956.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016302
  •  go-up   go-down


60. Cagle PT, Churg A: Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med; 2005 Nov;129(11):1421-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
  • CONTEXT: Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia.
  • DESIGN: Based on previous medical publications, extensive personal consultations, and experience on the United States-Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies.
  • RESULTS: Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult.
  • Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland.
  • Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion.
  • CONCLUSIONS: Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa.
  • Invasion is the most reliable criterion for determining that a mesothelial proliferation is malignant.
  • When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Hyperplasia / pathology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


61. Haga T, Nakajima Y, Kitamura A, Kuroda F, Takiguchi Y, Tatsumi K: [Case of benign asbestos pleurisy with diffuse pleural thickening confirmed on autopsy]. Nihon Kokyuki Gakkai Zasshi; 2010 Nov;48(11):821-4
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of benign asbestos pleurisy with diffuse pleural thickening confirmed on autopsy].
  • Thoracoscopic pleural biopsy was conducted to exclude malignant mesothelioma.
  • The patient's condition was diagnosed as benign asbestos pleurisy with diffuse pleural thickening.
  • We report a rare case of benign asbestos pleurisy with diffuse pleural thickening confirmed by autopsy.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141060.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem; 2009 Jul;42(10-11):1046-50
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
  • We assessed comparatively the diagnostic value of two potential malignant pleural mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin.
  • MATERIALS AND METHOD: We measured serum and pleural fluid values of mesothelin and hyaluronic acid in 76 patients with MPM, 33 patients with pleural metastases of carcinomas (Mets group) and 27 patients with benign pleural effusion related to asbestos exposure (BPLAE).
  • [MeSH-major] Hyaluronic Acid / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302997.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


63. Moyano Calvo JL, Giraldez Puig J, Sánchez de la Vega J, Dávalos Casanova G, Morales López A: [Adenomatoid tumor of the epididymis]. Actas Urol Esp; 2007 Apr;31(4):417-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis].
  • [Transliterated title] Tumor adenomatoide de epididimo.
  • OBJECTIVE: Paratesticular tumors are very rare and mostly bening.
  • Wa aport a new case of adenomatoid tumor of epididymis METHOD: Male of 40 years old with solid lesion in epidididymis tale treated with mass exéresis RESULTS: Adenoamotid tumor of the epididymis confirmed with hystopathologic technique CONCLUSION: Adenomatoid tumor of epididymis is the most frequent paratesticular tumors and when is suspected, conservative surgery must be performed.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633930.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Ohar JA, Ampleford EJ, Howard SE, Sterling DA: Identification of a mesothelioma phenotype. Respir Med; 2007 Mar;101(3):503-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a mesothelioma phenotype.
  • Despite the strong association of asbestos exposure to mesothelioma, only a fraction of persons exposed develop this neoplasm which is characterized by long latency and shortened survival.
  • Familial clustering implicates both exposure and genetic predisposition as causative, but a biologically relevant mesothelioma phenotype essential to genetic analysis has not been defined.
  • To identify a more extensive set of traits that would define a mesothelioma phenotype for the purpose of genetic analysis, we set to determine characteristics that distinguish mesothelioma patients from others exposed to asbestos and to identify factors that predict the presence of mesothelioma over other mesenchymal tumors of the peritoneum and carcinoma metastatic to the pleura.
  • We compared demographics in four asbestos-exposed groups (controls n=347, bronchogenic cancer n=67, mesothelioma n=179 and benign asbestos-induced lung disease (BALD) n=3757).
  • Within the mesothelioma group, we compared traits to identify characteristics associated with shortened survival.
  • We found that compared to other asbestos-exposed groups, subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a second cancer diagnosis (odds ratio=3.29), had a longer disease latency, and had a greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI 2.5-3.5).
  • Thoracic tumor location, work exposure and male gender were consistently associated with shortened survival (1.9+/-1.3 years).
  • We conclude that thoracic tumor location, work exposure, male gender, long latency, early age at first exposure, presence of a second cancer, and first-degree relative with cancer define a phenotype that sets mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / genetics. Occupational Diseases / genetics


65. King J, Thatcher N, Pickering C, Hasleton P: Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology; 2006 Dec;49(6):561-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
  • AIMS: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease.
  • Desmin and epithelial membrane antigen (EMA) were the most useful, with sensitivity and specificity both above 74%.
  • A high MCM2 labelling index also differentiated between benign and malignant pleural disease.
  • The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunohistochemistry / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Silver Staining
  • [MeSH-minor] Antigens, Nuclear. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Nuclear Proteins. Nucleolus Organizer Region / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163840.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  • [Number-of-references] 33
  •  go-up   go-down


66. Canedo-Patzi AM, León-Bojorge B, de Ortíz-Hidalgo C: [Adenomatoid tumor of the genital tract. Clinical, pathological and immunohistochemical study in 9 cases]. Gac Med Mex; 2006 Jan-Feb;142(1):59-66
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the genital tract. Clinical, pathological and immunohistochemical study in 9 cases].
  • [Transliterated title] Tumor adenomatoide del aparato genital, Estudio clinicopatológico e inmunohistoquímico de 9 casos.
  • OBJECTIVE: [corrected] Describe the histological andimmunohistochemicalfeatures of nine genital tract adenomatoid tumors.
  • MATERIAL AND METHODS: Nine cases of adenomatoid tumors were collected from the files of the Pathology department at a private hospital (ABC Hospital).
  • Tumors were studied from a histological and inmunohistochemical perspective.
  • Tumors were located in the uterus (seven),fallopian tube (one) and epididymis (one).
  • Tumor size ranged from 0.4 to 5.8 cm.
  • Arrangement of the neoplastic tubules around fascicles of smooth muscle; angiomatoidpattern with a peripheral location, and solid and adenoidpatterns with a central location in the tumor were some of the observed histological features.
  • Immunohistochemically all tumors exhibited strong and diffuse positivity for calretinin and AE1/AE3.
  • Thrombomodulin was positive in all tumors (focal and weak in angiomatoid pattern and diffuse and strong in adenoid and solid patterns).
  • The CK5/6 antibody was positive in seven tumors (diffuse in three and focal in four).
  • Two tumors were negative for this marker.
  • All tumors were negative for CD31.
  • CONCLUSIONS: The immunopheno type of the adenomatoid tumors in our series confirms their mesothelial origin.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Fallopian Tube Neoplasms / pathology. Genital Neoplasms, Male / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548294.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


67. Pila Pérez R, Rosales Torres P, Pila Peláez R, Holguín Prieto V, Torres Vargas E: [Adenomatoid tumor of the epididymis: an infrequent case]. Arch Esp Urol; 2009 Oct;62(8):656-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis: an infrequent case].
  • [Transliterated title] Tumor adenomatoide del epidídimo: una infrecuente observación.
  • OBJECTIVES: To present a new case of adenomatoid tumor of the epididymis, the first report in our hospital since 1962.
  • METHODS: We report a clinical case with a brief bibliographic review about adenomatoid tumor of the epididymis.
  • Physical examination and ultrasound study demonstrated a tumor of 5x5x2 cm.
  • It was removed and the histopathological study was compatible with adenomatoid tumor of the epididymis.
  • CONCLUSION: The adenomatoid tumor of the epididymis is a neoplasm located in the paratesticular region, however it can be found infrequently in other sites.
  • Mesothelial origin has been mentioned and inflammation has played some role in the development of these tumors.
  • It can minimally invade adjacent structures, though it is benign without metastatic potential.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893140.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


68. Nowak AK, Armato SG 3rd, Ceresoli GL, Yildirim H, Francis RJ: Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer; 2010 Oct;70(1):1-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
  • Imaging of malignant pleural mesothelioma (MPM) poses many challenges for imaging specialists and clinicians due to the anatomic location and unique growth pattern of this tumor.
  • Nevertheless, imaging in MPM plays a critical role in diagnosis, prognostication, prediction or measurement of response to therapy, and monitoring of disease recurrence after aggressive surgical management.
  • Imaging-based studies presented at the 9th International Conference of the International Mesothelioma Interest Group (IMIG) in October 2008 sought to further define the current practice and future potential of imaging for the mesothelioma patient.
  • At diagnosis, FDG-PET parameters had a high sensitivity and specificity for differentiation of benign from malignant pleural disease.
  • The use of FDG-PET to extract quantitative features from metabolically active tumor volume was shown to be a significant factor in the prediction of patient survival.
  • CT-based assessment of mesothelioma was determined to be inconsistent with spherical-model-based criteria so that changes in tumor area, a presumably more complete assessment of tumor burden, exhibited a 46% concordance rate with changes in linear measurements.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20541834.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102085
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Ireland
  •  go-up   go-down


69. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN: The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol; 2010 Dec;38(12):874-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
  • Pleural malignant mesothelioma (MM), which is an aggressive neoplasm with a high mortality, frequently manifests initially as pleural effusions.
  • We reviewed the cytologic findings in pleural effusions of a large series of histologically proven MM (234 cases) diagnosed in our institution between 2001 and 2008.
  • On review of the cytology slides, only four cases were upgraded from benign to suspicious compared to four cases downgraded from suspicious to atypical but no significant improvement to the diagnosis could be made on revision.
  • [MeSH-major] Cytodiagnosis / methods. Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20049969.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res; 2007 May 15;13(10):2928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
  • PURPOSE: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.
  • We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects.
  • EXPERIMENTAL DESIGN: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects.
  • However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure.
  • Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes.
  • Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Osteopontin / blood. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504993.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


71. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
  • Mesothelioma is an asbestos-related tumour.
  • Mesothelioma in the thorax occurs on the pleura and is known as pleural mesothelioma.
  • It is the more common form of mesothelioma, accounting for 70% of cases.
  • It accounts for much of the remaining 30% and is known as peritoneal mesothelioma.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • We update on the current understanding of peritoneal mesothelioma from a clinical perspective in hope that greater clinician awareness will promote best practice management of this condition.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


72. Gill RR, Gerbaudo VH, Sugarbaker DJ, Hatabu H: Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg; 2009;21(2):111-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current trends in radiologic management of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive pleural tumor with a complex growth pattern.
  • Perfusion CT can evaluate the microvasculature of tumors; however its disadvantages, such as high radiation exposure and side effects from iodinated contrast, have limited its use to research settings.
  • Magnetic resonance imaging (MRI) is superior to CT, both in the differentiation of malignant from benign pleural disease and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion and diffusion MRI are promising new techniques for the assessment of tumor cellularity and microvasculature and can be used for quantitative and qualitative assessment of treatment response.
  • Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for the differentiation of benign from malignant lesions, for staging, and for monitoring response to therapy.
  • PET-CT is superior to other imaging modalities in detecting more extensive disease involvement and identifying unsuspected occult distant metastases.
  • [MeSH-major] Magnetic Resonance Imaging / trends. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Positron-Emission Tomography / trends. Tomography, X-Ray Computed / trends
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pleural Effusion, Malignant / diagnosis. Predictive Value of Tests. Radiopharmaceuticals. Thoracic Surgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822282.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA116271
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 30
  •  go-up   go-down


73. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • CONCLUSION: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


74. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y: Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol; 2007 Feb;20(2):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.
  • The separation of benign reactive mesothelium (RM) from malignant mesothelial proliferation can be a major challenge.
  • A number of markers have been proposed, including epithelial membrane antigen, p53 protein, and P-glycoprotein.
  • To date, however, no immunohistochemical marker that allows unequivocal discrimination of RM from malignant pleural mesothelioma (MPM) has been available.
  • GLUT-1 is largely undetectable by immunohistochemistry in normal epithelial tissues and benign tumors, but is expressed in a variety of malignancies.
  • Recently, in fact, some studies have shown that GLUT-1 expression is useful for distinguishing benign from malignant lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Glucose Transporter Type 1 / metabolism. Immunoenzyme Techniques. Mesothelioma / metabolism. Pleural Neoplasms / metabolism. Pleurisy / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192790.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1
  •  go-up   go-down


75. Pu RT, Sheng ZM, Michael CW, Rhode MG, Clark DP, O'Leary TJ: Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study. Diagn Cytopathol; 2007 Aug;35(8):498-502
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study.
  • We tested whether methylation profiles generated by real-time methylation-specific PCR (MSP) can be useful in differentiating benign, reactive mesothelial cell proliferation (RM) from malignant mesothelioma (MM).
  • [MeSH-major] DNA Methylation. Epithelium / pathology. Mesothelioma / diagnosis. Mesothelioma / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17636483.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


76. Davidson B, Dong HP, Holth A, Berner A, Risberg B: Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol; 2007 May;127(5):752-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
  • We studied chemokine receptor expression in malignant mesothelioma (MM), reactive mesothelium (RM), and leukocytes in effusions.
  • Chemokine receptors are widely expressed on leukocytes in MM and RM effusions but are infrequently found on cells of mesothelial origin.
  • This finding suggests a major role for an autocrine chemokine pathway in leukocytes but not in MM cells.
  • The increased monocyte infiltration and their higher chemokine receptor expression in MM effusions may have a tumor-promoting rather than tumor-inhibiting effect.
  • [MeSH-major] Epithelial Cells / immunology. Leukocytes / immunology. Mesothelioma / immunology. Receptors, Chemokine / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439834.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; 0 / Receptors, Interleukin-8A
  •  go-up   go-down


77. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol; 2008 Aug;3(8):851-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
  • INTRODUCTION: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma.
  • Three potential markers for mesothelioma are mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin.
  • The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers.
  • METHODS: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies.
  • RESULTS: Serum levels of the three markers were elevated in mesothelioma patients.
  • At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin.
  • Osteopontin and MPF were unable to differentiate patients with mesothelioma from patients with other malignancies or those presenting with transudative pleural effusions.
  • Combining the data from the three biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone.
  • CONCLUSION: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670302.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


78. Garrido Abad P, Jiménez Gálvez M, Herranz Fernández LM, Bocardo Fajardo G, Arellano Gañán R, Pereira Sanz I: [Adenomatoid tumor of the epididymis. Report of two cases]. Arch Esp Urol; 2007 Jul-Aug;60(6):700-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis. Report of two cases].
  • [Transliterated title] Tumor adenomatoide de epidídimo. Aportación de dos casos.
  • OBJECTIVE: Tumors of the epididymis are rare.
  • They are unusually benign and adenomatoid tumors are the most frequent.
  • Report of two cases of this kind of tumor of the epididymis.
  • METHODS/RESULTS: We report two cases of adenomatoid tumor of the epididymis diagnosed at our hospital during last year.
  • Pathological diagnosis was adenomatoid tumor.
  • CONCLUSIONS: The majority of epididymal tumors follow a benign course.
  • In the finding of an epididymal mass, after palpation and imaging tests, organ sparing surgery (epididymectomy) is recommended.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847749.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • The subcutis is a particularly rare site of metastatic sarcomatoid mesothelioma.
  • It is essential to differentiate neoplasm metastatic to the skin and subcutis from primary and benign lesions of the same region.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


80. Morokawa N, Takayanagi N, Ubukata M, Kurashima K, Yoned K, Tsuchiy N, Miyahara Y, Yamaguchi S, Tokunaga D, Saito H, Yanagisawa T, Sugita Y, Kawabata Y: [Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy]. Nihon Kokyuki Gakkai Zasshi; 2008 May;46(5):368-73
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy].
  • Thoracoscopic pleural biopsy was conducted in 2001 to exclude pleural malignant mesothelioma.
  • After 3-year observation and excluding other causes, he was given a diagnosis of benign asbestos pleurisy.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18517012.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


81. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
  • Expression of the 67-kd laminin receptor (67-kd LR) has been reported in a wide range of carcinomas, in many of which it correlated with poor differentiation, metastasis, disease progression, and poor survival.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Mesothelioma / metabolism. Pleural Effusion, Malignant / metabolism. Receptors, Laminin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


82. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol; 2008 Nov;3(11):1317-24
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
  • INTRODUCTION AND METHODS: We investigated the diagnostic and prognostic value of soluble mesothelin-related proteins (SMRP) in sera from patients with newly diagnosed malignant pleural mesothelioma (MPM) (n = 100), MPM patients at tumor relapse (n = 29), primary lung cancer (n = 139), and benign asbestosis (n = 75) using Mesomark--enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • RESULTS: SMRP concentrations were significantly higher in MPM compared with benign asbestosis (p < 0.001) or lung cancer (p < 0.001).
  • Nevertheless, subtype-driven reanalysis showed only a trend in epithelial MPM.
  • [MeSH-major] Asbestosis / diagnosis. Biomarkers, Tumor / blood. Lung Neoplasms / diagnosis. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Asbestosis.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978568.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


83. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest; 2007 Oct;132(4):1239-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
  • BACKGROUND: Malignant mesothelioma is an aggressive, uniformly fatal tumor.
  • Serum markers would be useful for the diagnosis of this disease.
  • The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma.
  • METHODS: Serum levels of mesothelin and CA125 were determined by commercially available assays in 117 samples obtained at diagnosis from patients with pleural malignant mesothelioma, 33 healthy, asbestos-exposed individuals, 53 patients with asbestos-related lung or pleural disease, and 30 patients presenting with benign pleural effusions.
  • RESULTS: CA125 had a cross-validated sensitivity of 27% for mesothelioma patients at a specificity of 95% relative to asbestos-exposed individuals, or 50% relative to individuals with benign pleural effusions.
  • Mesothelin had a cross-validated sensitivity of 52% for mesothelioma patients, at a sensitivity of 95% relative to individuals with benign lung or pleural disease.
  • CA125 and mesothelin levels were discordant in > 50% of mesothelioma patients.
  • Combining the data from the two biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone.
  • CONCLUSION: Combining mesothelin and CA125 data does not improve the sensitivity of mesothelioma diagnosis over mesothelin alone.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646232.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


84. Butnor KJ: My approach to the diagnosis of mesothelial lesions. J Clin Pathol; 2006 Jun;59(6):564-74
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to the diagnosis of mesothelial lesions.
  • Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies.
  • Immunohistochemical markers can aid in distinguishing epithelioid malignant mesothelioma from metastatic adenocarcinoma, but because no single marker reliably separates all cases, a panel of stains is recommended.
  • Immunohistochemical studies are of more limited value in sarcomatoid malignant mesothelioma, and other features often play an essential role.
  • The separation of reactive mesothelial proliferations from malignant mesothelioma on small biopsy can be quite difficult, as distinguishing features, such as stromal invasion, often cannot be adequately assessed.
  • In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):25-30 [9253621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1399-408 [9414183.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):85-9 [9426522.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):166-9 [9490276.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):73-8 [9500194.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):285-92 [9580050.001]
  • [Cites] Histopathology. 1998 Mar;32(3):209-16 [9568505.001]
  • [Cites] Histopathology. 1998 May;32(5):462-72 [9639123.001]
  • [Cites] Histopathology. 2000 Sep;37(3):224-31 [10971698.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1545-9 [11090371.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1316-20 [11570906.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Arch Pathol Lab Med. 2001 Dec;125(12):1588-90 [11735696.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):191-9 [9704618.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):182-8 [9754650.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1215-21 [9777983.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):929-33 [9796717.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):313-23 [10088551.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):105-10 [15389250.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Thorac Imaging. 2003 Jul;18(3):200-3 [12867819.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):444-52 [14636270.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):534-40 [15087673.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] Am J Clin Pathol. 1976 Feb;65(2):159-67 [175652.001]
  • [Cites] Am J Pathol. 1982 Jul;108(1):80-8 [6178295.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):215-22 [7102900.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):62-6 [3099726.001]
  • [Cites] Pathol Annu. 1987;22 Pt 2:91-131 [2825103.001]
  • [Cites] Ultrastruct Pathol. 1987;11(5-6):503-33 [3318058.001]
  • [Cites] Ultrastruct Pathol. 1988;12(4):367-84 [2458647.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:303-53 [2654842.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 2000 Apr;36(4):341-7 [10759948.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):759-66 [2193875.001]
  • [Cites] Histopathology. 1992 Jan;20(1):47-51 [1310669.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):295-8 [1577967.001]
  • [Cites] Histopathology. 1992 Nov;21(5):453-7 [1280615.001]
  • [Cites] Histopathology. 1993 Jun;22(6):601-2 [8354495.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):753-7 [7520015.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):30-44 [7770673.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):189-94 [8607443.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1037-46 [8764740.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1147-52 [8822117.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9 [15722797.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):34-48 [16056246.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1203-14 [9777982.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):649-54 [10800396.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] J Postgrad Med. 2002 Jan-Mar;48(1):29-31 [12082324.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Histopathology. 2002 Oct;41(4):301-7 [12383211.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3443-8 [12552937.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):29-34 [10665909.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):107-12 [10697265.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):598-606 [10757409.001]
  • (PMID = 16731600.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1860395
  •  go-up   go-down


85. Wheeler YY, Burroughs F, Li QK: Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature. Diagn Cytopathol; 2009 Oct;37(10):748-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature.
  • Well-differentiated papillary mesothelioma (WDPM) is an uncommon subtype of epithelioid mesothelioma.
  • In contrast to malignant epithelioid mesothelioma, WDPM has a low malignant potential and an indolent clinical course.
  • WDPM may be difficult to diagnose and differentiate from benign reactive mesothelial cells and other malignant neoplasm on cytology specimens due to the presence of papillary or tubulopapillary clusters of tumor cells.
  • We report a case of a 63-year-old Asian male with a slowly growing left inguinal hernia mass for several years and a concurrent 8 cm mass in the peritoneal wall.
  • The cytology of ultrasound-guided fine-needle aspiration (FNA) of the left inguinal hernia and peritoneal masse reveal cellular specimens with numerous individual and tubulopapillary clusters of epithelioid mesothelial cells in a background of scant hyalinized material.
  • Tumor cells show minimal cytological atypia.
  • The differential diagnoses are broad and include reactive mesothelial cells, WDPM, and other malignant neoplasm.
  • It is important to recognize this entity in the differential diagnosis, because the clinical management of WDPM is quite different from that of malignant neoplasm.
  • [MeSH-major] Hernia, Inguinal / pathology. Inguinal Canal / pathology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19373910.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


86. Greillier L, Astoul P: Mesothelioma and asbestos-related pleural diseases. Respiration; 2008;76(1):1-15
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma and asbestos-related pleural diseases.
  • We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis.
  • Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area.
  • [MeSH-major] Asbestosis. Mesothelioma. Pleural Diseases. Pleural Neoplasms

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18583923.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 189
  •  go-up   go-down


87. Safioleas MC, Constantinos K, Michael S, Konstantinos G, Constantinos S, Alkiviadis K: Benign multicystic peritoneal mesothelioma: a case report and review of the literature. World J Gastroenterol; 2006 Sep 21;12(35):5739-42
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign multicystic peritoneal mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: a case report and review of the literature.
  • Benign multicystic peritoneal mesothelioma (BMPM) is a rare tumor that occurs mainly in women in their reproductive age.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Mesothelioma, Cystic / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasms / diagnosis. Neoplasms / etiology. Neoplasms / pathology. Neoplasms / surgery

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 2000 May;82(3):196-7 [10858684.001]
  • [Cites] Mayo Clin Proc. 1982 Oct;57(10):634-8 [7121070.001]
  • [Cites] Pathol Annu. 1989;24 Pt 2:1-21 [2671878.001]
  • [Cites] J Urol. 1990 Feb;143(2):347-8 [2299728.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):375-8 [2181883.001]
  • [Cites] Am J Clin Pathol. 1990 Dec;94(6):758-61 [1700878.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):169-71 [1734224.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Dec;71(8):642-4 [1336927.001]
  • [Cites] J Clin Pathol. 1993 Sep;46(9):867-8 [8227441.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2B):715-20 [7516639.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):377-80 [8088617.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):901-3 [7724156.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):157-60 [7773468.001]
  • [Cites] Histopathology. 1995 Nov;27(5):479-81 [8575742.001]
  • [Cites] Histopathology. 1996 Oct;29(4):375-7 [8910046.001]
  • [Cites] J Clin Pathol. 1986 Apr;39(4):440-5 [2422221.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):844-54 [3789251.001]
  • [Cites] Histopathology. 1988 May;12(5):555-8 [3294158.001]
  • [Cites] Am J Surg Pathol. 1988 Oct;12(10):737-46 [3421410.001]
  • [Cites] Radiology. 1989 Feb;170(2):333-7 [2643136.001]
  • [Cites] Diagn Cytopathol. 1989;5(1):14-21 [2656144.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):174-9 [9161783.001]
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):131-3 [9698490.001]
  • [Cites] Abdom Imaging. 1998 Sep-Oct;23(5):502-4 [9841063.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):166-75 [9989843.001]
  • [Cites] BJU Int. 1999 Sep;84(4):533-4 [10468779.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):582-90 [10493628.001]
  • [Cites] Magy Seb. 2005 Feb;58(1):35-7 [16018599.001]
  • [Cites] Pol J Pathol. 2005;56(2):81-7 [16092670.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1101-7 [16343188.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jul;13(3):273-8 [7928060.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1205-7 [7528798.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):399-400 [11328842.001]
  • [Cites] Cesk Patol. 2000 Oct;36(4):160-2 [11378909.001]
  • [Cites] ANZ J Surg. 2001 Oct;71(10):615-8 [11552941.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):192-5 [11884057.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):220 [11961660.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1523-7 [12409730.001]
  • [Cites] Z Gastroenterol. 2003 Apr;41(4):329-32 [12695939.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):31-5 [12729358.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):517-8 [12789944.001]
  • [Cites] J Obstet Gynaecol. 2003 Sep;23(5):576 [12963534.001]
  • [Cites] Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S41-3 [14727459.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Cancer. 1980 May 1;45(9):2395-9 [7379036.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • (PMID = 17007034.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 49
  • [Other-IDs] NLM/ PMC4088182
  •  go-up   go-down


88. Demirag F, Unsal E, Tastepe I: Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature. Lung Cancer; 2007 Aug;57(2):233-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature.
  • This report describes two cases of diffuse biphasic malignant mesothelioma with osseous differentiation and long survival.
  • Epithelioid tumor cells as well as benign osteoclasts within the ossification reacted positively for cytokeratin 5/6, whereas sarcomatoid areas were negative.
  • To our knowledge, these two cases with biphasic malignant mesothelioma and osseous differentiation with long survival are the first to be described from Central Anatolia.
  • [MeSH-major] Mesothelioma / pathology. Ossification, Heterotopic. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Asbestosis / complications. Asbestosis / pathology. Biomarkers, Tumor / metabolism. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-5 / metabolism. Keratin-6 / metabolism. Male. Middle Aged. Osteoclasts / metabolism. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363104.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 0 / Keratin-5; 0 / Keratin-6
  • [Number-of-references] 24
  •  go-up   go-down


89. Hasteh F, Lin GY, Weidner N, Michael CW: The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol; 2010 Apr 25;118(2):90-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
  • BACKGROUND: The distinction of benign from malignant mesothelial proliferations in cytologic specimens can be problematic.
  • METHODS: Archival paraffin-embedded cell blocks of pleural and peritoneal fluids from 52 patients with malignant mesothelioma (MM) and 64 patients with reactive mesothelial hyperplasia (MH) were retrieved.
  • IHC stains included desmin, epithelial membrane antigen (EMA), glucose-transport protein 1 (GLUT-1), Ki67, and p53.
  • EMA was positive in 9% (6 of 64) of benign and 100% (52 of 52) of malignant cases (P < .001).
  • GLUT-1 was positive in 12% (5 of 43) of benign and 47% (7 of 15) of malignant cases.
  • Ki67 showed strong nuclear positivity in >40% of mesothelial cells in 9% (6 of 64) of benign and 16% (8 of 49) of malignant cases (P = .38).
  • p53 showed strong nuclear positivity in 2% (1 of 46) of benign and 47% (7 of 15) of malignant cases (P < .001).
  • Likewise, strong membranous positivity for GLUT-1 and/or strong nuclear staining for p53 favors a mesothelioma.
  • [MeSH-major] Ascitic Fluid / metabolism. Epithelium / pathology. Immunohistochemistry. Mesothelioma / diagnosis. Pleural Effusion / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Desmin / analysis. Excitatory Amino Acid Transporter 2 / analysis. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Mucin-1 / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [CommentIn] Cancer Cytopathol. 2010 Aug 25;118(4):225; author reply 225 [20731007.001]
  • (PMID = 20209622.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Desmin; 0 / Excitatory Amino Acid Transporter 2; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


90. Saad RS, Cho P, Liu YL, Silverman JF: The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol; 2005 Mar;32(3):156-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
  • Differentiating reactive mesothelial (RM) proliferation from malignant mesothelioma (MM) can be cytologically challenging.
  • There have been discordant studies reporting the value of epithelial membrane antigen (EMA) in differentiating RM from MM.
  • [MeSH-major] Mesothelioma / diagnosis. Mucin-1 / metabolism. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690334.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


91. Cakir C, Gulluoglu MG, Yilmazbayhan D: Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology; 2006 Feb;38(1):10-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
  • AIMS: The differential diagnosis of malignant mesothelioma (MM) from benign mesothelial lesions (BML) based on histopathological criteria is sometimes not satisfying and causes diagnostic problems for histopathologists.
  • METHODS: Sixty-six cases of MM (33 epithelioid, 30 biphasic and 3 sarcomatoid) and 22 cases of BML (15 reactive mesothelial proliferations and 7 fibrous pleuritis/pericarditis) were included in this study.
  • CONCLUSION: As a result, being cheap and simple methods, Ki-67 and hTERT immunohistochemistries can be used in differentiating malignant and benign mesothelial lesions in routine formalin-fixed, paraffin-embedded material.
  • [MeSH-major] Cell Proliferation. Neoplasms, Mesothelial / metabolism. Neoplasms, Mesothelial / pathology. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Pleurisy / diagnosis. Pleurisy / metabolism. Pleurisy / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484001.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


92. Yamamoto Y, Kameyama R, Togami T, Kimura N, Ishikawa S, Yamamoto Y, Nishiyama Y: Dual time point FDG PET for evaluation of malignant pleural mesothelioma. Nucl Med Commun; 2009 Jan;30(1):25-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
  • OBJECTIVE: To evaluate whether 2-deoxy-2-18F-fluoro-D-glucose (FDG) positron emission tomography (PET) is more useful in differentiating malignant from benign pleural lesions, and whether delayed FDG PET imaging can improve the diagnostic performance in patients with suspicion of malignant pleural mesothelioma (MPM).
  • RESULTS: The final diagnosis was MPM in 17 patients and benign pleural disease in 16 patients.
  • The mean values of SUVearly and SUVdelayed in MPM were significantly higher than the corresponding values in benign pleural disease (P < 0.01, respectively).
  • [MeSH-major] Fluorodeoxyglucose F18. Mesothelioma / pathology. Mesothelioma / radionuclide imaging. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306511.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


93. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
  • Differentiating cells of mesothelial origin from adenocarcinoma (ACA) based on morphology alone can be a diagnostic challenge, especially in cytological specimens.
  • Malignant mesothelioma (MM) is characterized by accumulation of abundant intracellular hyaluronic acid (HA), a feature that is not reported in ACA.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • In MM and reactive mesothelial cells, CD44S stained cell membranes diffusely with highlights on the villous surfaces and in ACA it was focal and confined to cell membranes.
  • Immunostaining with HA is a reliable marker that can distinguish between cells of mesothelial origin (reactive mesothelial cells and MM) and ACA.
  • The CD44S staining pattern of cells of mesothelial origin is of diagnostic significance.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


94. Hamamatsu A, Arai T, Iwamoto M, Kato T, Sawabe M: Adenomatoid tumor of the adrenal gland: case report with immunohistochemical study. Pathol Int; 2005 Oct;55(10):665-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: case report with immunohistochemical study.
  • Adrenal adenomatoid tumor (AT) is a recently recognized disease with marked male predominance.
  • Herein is presented a case of adrenal AT incidentally found in a 30-year-old man and results of immunohistochemical examination of the tumor.
  • Cut surface showed a relatively well-circumscribed firm tumor with a white solid appearance.
  • Histologically, the tumor had the typical appearance of AT described in the genital tract.
  • Immunohistochemically, the tumor cells were positive for calretinin, D2-40, WT1, mesothelial cell antigen, CA125, thrombomodulin, vimentin and cytokeratins (stained by AE1 + AE3, OV-TL 12/30, CAM5.2 and MNF116), and negative for endothelial markers (CD31, CD34 and factor VIII-related antigen) and CD56.
  • CD56-positive adrenocortical cells were diffusely scattered in the tumor, especially in its periphery.
  • These findings confirm mesothelial origin of the tumor and suggest that this tumor has little relation to sex hormone despite male predominance.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Coronary Thrombosis / mortality. Coronary Thrombosis / pathology. Fatal Outcome. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185299.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Kilic N, Tilki D, Ergün B, Seitz M, Stief CG, Reich O, Ergün S: Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor. Anticancer Res; 2010 Jul;30(7):2651-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor.
  • BACKGROUND/AIM: To study the expression of the pro-angiogenic factor carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in epididymal adeno-matoid tumor tissue, a very rare benign neoplasia, in relation to its vascularization.
  • MATERIALS AND METHODS: Immunohistochemistry for CEACAM1 and for both endothelial markers CD31 and CD34 was performed in normal human epididymal and epididymal adenomatoid tumor tissue.
  • The vessel density was calculated in four tumor regions with different degrees of vascularization in comparison to the vascularization of the normal epididymal tissue.
  • RESULTS: CEACAM1 was found in normal epididymal epithelium, while the epithelium of tumor glands was mostly negative.
  • Only few blood vessels and lymphatics in adenomatoid tumor tissue expressed CEACAM1.
  • The assessment of vascularization revealed either equal or a significantly lower vessel density in some adenomatoid tumor regions in comparison to normal epididymal tissue.
  • DISCUSSION: These data demonstrate that despite its epithelial down-regulation, CEACAM1 is not present in the majority of adenomatoid tumor blood vessels, which might be related to the lower angiogenic activity and benign behaviour of this tumor.
  • [MeSH-major] Adenomatoid Tumor / blood supply. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Testicular Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Endothelial Cells / metabolism. Epididymis / blood supply. Epididymis / metabolism. Epithelial Cells / metabolism. Humans. Immunohistochemistry. Male. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682994.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


96. Chung CT, Santos Gda C, Hwang DM, Ludkovski O, Pintilie M, Squire JA, Tsao MS: FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol; 2010 Jul;63(7):630-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
  • AIMS: To develop a fluorescence in-situ hybridisation (FISH) assay for detecting p16/CDKN2A deletion on paraffin tissue sections for use as an ancillary test to distinguish reactive from malignant mesothelial proliferations.
  • METHOD: Dual-colour FISH for p16/CDKN2A and chromosome 9 (CEP-9) was performed on 11 benign mesothelial proliferations and 54 malignant pleural mesothelioma (MPM) cases to establish cut-off values for p16/CDKN2A deletion.
  • RESULTS: Cut-off values for p16/CDKN2A deletion were calculated based on FISH signalling patterns obtained from the benign controls (mean percent nuclei plus three standard deviations).
  • None of the benign cases showed a homozygous deletion pattern (no p16/CDKN2A, at least one CEP-9 signal).
  • CONCLUSION: Distinction between benign and malignant mesothelial proliferations can be diagnostically challenging.
  • [MeSH-major] Gene Deletion. Genes, p16. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4547-51 [12907630.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] J Pathol. 2003 Nov;201(3):355-62 [14595746.001]
  • [Cites] J Pathol. 1992 May;167(1):1-4 [1320670.001]
  • [Cites] Virchows Arch. 2008 Dec;453(6):627-35 [18958493.001]
  • [Cites] J Pathol. 1992 Dec;168(4):377-81 [1484319.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Hum Pathol. 1994 May;25(5):443-8 [8200637.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5547-51 [7923195.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):511-5 [7630635.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):649-53 [9466670.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):143-8 [15571800.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3303-8 [15867227.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):320-4 [16240396.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Histopathology. 2006 Dec;49(6):561-8 [17163840.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):215-20 [17192790.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):742-7 [18327208.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):51-6 [12589646.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] J Pathol. 1999 Oct;189(2):251-7 [10547583.001]
  • [Cites] J Pathol. 1992 May;167(1):5-8 [1352542.001]
  • (PMID = 20591913.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Other-IDs] NLM/ PMC2989172
  •  go-up   go-down


97. Rekhi B, Pathuthara S, Ajit D, Kane SV: "Signet-ring" cells--a caveat in the diagnosis of a diffuse peritoneal mesothelioma occurring in a lady presenting with recurrent ascites: an unusual case report. Diagn Cytopathol; 2010 Jun;38(6):435-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Signet-ring" cells--a caveat in the diagnosis of a diffuse peritoneal mesothelioma occurring in a lady presenting with recurrent ascites: an unusual case report.
  • A diffuse peritoneal mesothelioma is a rare tumor.
  • Exfoliative cytology forms the first step in the diagnosis of mesothelioma, since most of these cases presented with effusion.
  • Despite well established cytomorphological features, a challenge exists in differentiating mesothelial cells, including reactive and malignant types from carcinoma cells and macrophages.
  • Presence of "signet-ring" cells increases the diagnostic challenge as these can be forms of benign and malignant cells.
  • We report an unusual case study of a diffuse peritoneal mesothelioma in a 57-years-old lady, with no history of asbestos exposure, presenting with recurrent ascites, diagnosed on ascitic fluid cytology and on histology as an adenocarcinoma, based upon the presence of "signet-ring" cells.
  • [MeSH-major] Ascites / etiology. Carcinoma, Signet Ring Cell / pathology. Diagnostic Errors. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19937944.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Barry P, Chan KG, Hsu J, Quek ML: Adenomatoid tumor of the tunica albuginea. Int J Urol; 2005 May;12(5):516-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the tunica albuginea.
  • Adenomatoid tumors are benign mesothelial tumors most commonly found in the paratesticular structures, especially the epididymis.
  • Herein, we report a case of adenomatoid tumor originating in the tunica albuginea and mimicking an intratesticular neoplasm.
  • We review the ultrasonographic presentation and literature regarding adenomatoid tumors originating in the tunica albuginea and testicular parenchyma.
  • [MeSH-major] Adenomatoid Tumor / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948758.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


99. Lanneau GS, McLaughlin D, O'Boyle J, Magann EF, Morrison JC: Well-differentiated papillary mesothelioma of the uterine serosa identified at cesarean section: a case report. J Reprod Med; 2005 Nov;50(11):860-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary mesothelioma of the uterine serosa identified at cesarean section: a case report.
  • BACKGROUND: Peritoneal mesotheliomas encompass a variety of benign and malignant neoplasms.
  • Well-differentiated papillary mesothelioma (WDPM) is uncommon, is thought to be of low malignant potential and is often discovered incidentally during abdominal or pelvic surgery.
  • A 2-cm, polypoid lesion was excised from the posterior uterine fundus; final pathology showed well-differentiated papillary mesothelioma.
  • A follow-up laparoscopic examination with abdominal washing for cytology and peritoneal biopsies revealed no residual disease.
  • Knowledge of the variable disease spectrum of mesothelioma is important in patient counseling and management.
  • Differentiating between WDPM and malignant mesothelioma, other peritoneal tumors and implants from primary sites is necessary to avoid overtreatment.
  • [MeSH-major] Cesarean Section. Mesothelioma / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419636.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Terra Filho M, de Freitas JB, Nery LE: [Asbestos-related diseases]. J Bras Pneumol; 2006;32 Suppl 2:S48-53
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latest diagnostic, radiological, computed tomography and lung function aspects of benign pleural disease, asbestosis, occupational lung cancer and mesothelioma are discussed.
  • [MeSH-minor] Humans. Lung Neoplasms / etiology. Mesothelioma / etiology. Pleural Diseases / etiology. Tomography, X-Ray Computed. Tuberculosis, Pulmonary / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273598.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 29
  •  go-up   go-down






Advertisement